US20050009866A1 - Treatment of cardiovascular disease with quinolinone enantiomers - Google Patents
Treatment of cardiovascular disease with quinolinone enantiomers Download PDFInfo
- Publication number
- US20050009866A1 US20050009866A1 US10/435,999 US43599903A US2005009866A1 US 20050009866 A1 US20050009866 A1 US 20050009866A1 US 43599903 A US43599903 A US 43599903A US 2005009866 A1 US2005009866 A1 US 2005009866A1
- Authority
- US
- United States
- Prior art keywords
- flosequinan
- enantiomer
- subject
- enantiomers
- purified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 33
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title description 24
- 238000011282 treatment Methods 0.000 title description 17
- UYGONJYYUKVHDD-UHFFFAOYSA-N flosequinan Chemical compound C1=C(F)C=C2N(C)C=C(S(C)=O)C(=O)C2=C1 UYGONJYYUKVHDD-UHFFFAOYSA-N 0.000 claims abstract description 126
- 229960001606 flosequinan Drugs 0.000 claims abstract description 120
- 238000000034 method Methods 0.000 claims abstract description 55
- 208000024891 symptom Diseases 0.000 claims description 41
- 206010019280 Heart failures Diseases 0.000 claims description 32
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 26
- 206010020772 Hypertension Diseases 0.000 claims description 22
- 230000002829 reductive effect Effects 0.000 claims description 17
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 11
- 229910002651 NO3 Inorganic materials 0.000 claims description 8
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 claims description 6
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 6
- 230000001077 hypotensive effect Effects 0.000 claims description 6
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 claims description 6
- 229960005450 eritrityl tetranitrate Drugs 0.000 claims description 5
- 229960000201 isosorbide dinitrate Drugs 0.000 claims description 5
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 4
- 229960003827 isosorbide mononitrate Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 abstract description 72
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract description 42
- 238000009472 formulation Methods 0.000 abstract description 9
- 150000002823 nitrates Chemical class 0.000 abstract description 7
- 150000002826 nitrites Chemical class 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 description 59
- 230000036772 blood pressure Effects 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- -1 sulphinyl Chemical group 0.000 description 17
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 102000010989 Type 6 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 13
- 108010037638 Type 6 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 13
- 125000003545 alkoxy group Chemical group 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 102000010861 Type 3 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 11
- 108010037543 Type 3 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 11
- 229930185107 quinolinone Natural products 0.000 description 11
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 9
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000000241 respiratory effect Effects 0.000 description 9
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 210000001367 artery Anatomy 0.000 description 7
- 238000009835 boiling Methods 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 108010028584 nucleotidase Proteins 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 238000003345 scintillation counting Methods 0.000 description 7
- 239000003998 snake venom Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 6
- 0 [1*]N1C=CC(=O)C([3*])=C1[2*] Chemical compound [1*]N1C=CC(=O)C([3*])=C1[2*] 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000003276 anti-hypertensive effect Effects 0.000 description 6
- 239000011928 denatured alcohol Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 229940094720 viagra Drugs 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000012265 solid product Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000012899 standard injection Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 4
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 4
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 101150098694 PDE5A gene Proteins 0.000 description 4
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 description 4
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 4
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 4
- 125000001589 carboacyl group Chemical group 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 125000001475 halogen functional group Chemical group 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- DLEBOPPNWGZOHU-UHFFFAOYSA-N 4-methyl-6-methylsulfinylthieno[3,2-b]pyridin-7-one Chemical compound CN1C=C(S(C)=O)C(=O)C2=C1C=CS2 DLEBOPPNWGZOHU-UHFFFAOYSA-N 0.000 description 3
- AYHHYAOIZZJEGB-UHFFFAOYSA-N 4-methyl-7-oxothieno[3,2-b]pyridine-6-carboxamide Chemical compound CN1C=C(C(N)=O)C(=O)C2=C1C=CS2 AYHHYAOIZZJEGB-UHFFFAOYSA-N 0.000 description 3
- PPEOTBRUHQKTHN-UHFFFAOYSA-N 7-chloro-1-methyl-4-oxoquinoline-3-carboxamide Chemical compound C1=C(Cl)C=C2N(C)C=C(C(N)=O)C(=O)C2=C1 PPEOTBRUHQKTHN-UHFFFAOYSA-N 0.000 description 3
- GWIZNOQICBSENV-UHFFFAOYSA-N 7-chloro-n,1-dimethyl-4-oxoquinoline-3-sulfonamide Chemical compound ClC1=CC=C2C(=O)C(S(=O)(=O)NC)=CN(C)C2=C1 GWIZNOQICBSENV-UHFFFAOYSA-N 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 241000288140 Gruiformes Species 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000037656 Respiratory Sounds Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000010256 biochemical assay Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229940029575 guanosine Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 206010037833 rales Diseases 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 229960002639 sildenafil citrate Drugs 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- PBYMYAJONQZORL-UHFFFAOYSA-N 1-methylisoquinoline Chemical compound C1=CC=C2C(C)=NC=CC2=C1 PBYMYAJONQZORL-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- OCMNQBTVMSWJHC-UHFFFAOYSA-N 7-fluoro-1-methyl-2,4-dioxoquinoline-3-carboxamide Chemical compound C1=C(F)C=C2N(C)C(=O)C(C(N)=O)C(=O)C2=C1 OCMNQBTVMSWJHC-UHFFFAOYSA-N 0.000 description 2
- ZUMVHPMHCIKNFT-UHFFFAOYSA-N 7-fluoro-1-methyl-3-methylsulfonylquinolin-4-one Chemical compound C1=C(F)C=C2N(C)C=C(S(C)(=O)=O)C(=O)C2=C1 ZUMVHPMHCIKNFT-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010060965 Arterial stenosis Diseases 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 206010048671 Venous stenosis Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002160 alpha blocker Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 241001515942 marmosets Species 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000010349 pulsation Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000000779 thoracic wall Anatomy 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- SNHIIPIPFWKWIA-UHFFFAOYSA-N (1-methyl-4-oxoquinolin-3-yl) methanesulfonate Chemical compound C1=CC=C2N(C)C=C(OS(C)(=O)=O)C(=O)C2=C1 SNHIIPIPFWKWIA-UHFFFAOYSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- UZWAHQKAIZUPJV-UHFFFAOYSA-N 1-methyl-3-methylsulfinylquinolin-4-one Chemical compound C1=CC=C2N(C)C=C(S(C)=O)C(=O)C2=C1 UZWAHQKAIZUPJV-UHFFFAOYSA-N 0.000 description 1
- XOQQVKDBGLYPGH-UHFFFAOYSA-N 2-oxo-1h-quinoline-3-carboxylic acid Chemical group C1=CC=C2NC(=O)C(C(=O)O)=CC2=C1 XOQQVKDBGLYPGH-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- PVQJJFKLQGNQMX-UHFFFAOYSA-N 4-methyl-6-methylsulfanylthieno[3,2-b]pyridin-7-one Chemical compound O=C1C(SC)=CN(C)C2=C1SC=C2 PVQJJFKLQGNQMX-UHFFFAOYSA-N 0.000 description 1
- CHODTZCXWXCALP-UHFFFAOYSA-N 5-bromoquinoline Chemical compound C1=CC=C2C(Br)=CC=CC2=N1 CHODTZCXWXCALP-UHFFFAOYSA-N 0.000 description 1
- PYGMPFQCCWBTJQ-UHFFFAOYSA-N 5-nitroisoquinoline Chemical compound N1=CC=C2C([N+](=O)[O-])=CC=CC2=C1 PYGMPFQCCWBTJQ-UHFFFAOYSA-N 0.000 description 1
- PSDVUIDSZMQDJU-UHFFFAOYSA-N 7-chloro-1-methylquinolin-4-one Chemical compound C1=C(Cl)C=C2N(C)C=CC(=O)C2=C1 PSDVUIDSZMQDJU-UHFFFAOYSA-N 0.000 description 1
- KVGQFTUVCDHXBT-UHFFFAOYSA-N 7-fluoro-1,3-dimethylquinoline-4-thione Chemical compound FC1=CC=C2C(=S)C(C)=CN(C)C2=C1 KVGQFTUVCDHXBT-UHFFFAOYSA-N 0.000 description 1
- NMKTYMAOLYZLRJ-UHFFFAOYSA-N 7-fluoro-1-methyl-4-oxoquinoline-3-carboxamide Chemical compound C1=C(F)C=C2N(C)C=C(C(N)=O)C(=O)C2=C1 NMKTYMAOLYZLRJ-UHFFFAOYSA-N 0.000 description 1
- SUXMGKFFQJTYEX-UHFFFAOYSA-N 8-nitroisoquinoline Chemical compound C1=NC=C2C([N+](=O)[O-])=CC=CC2=C1 SUXMGKFFQJTYEX-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 240000000850 Astartea fascicularis Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000004652 Cardiovascular Abnormalities Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- UTMPAWWHYWIENZ-UHFFFAOYSA-N O=[N+]([O-])OC1CCOCC2C(O[N+](=O)[O-])CCOCC12 Chemical compound O=[N+]([O-])OC1CCOCC2C(O[N+](=O)[O-])CCOCC12 UTMPAWWHYWIENZ-UHFFFAOYSA-N 0.000 description 1
- SNFOERUNNSHUGP-UHFFFAOYSA-N O=[N+]([O-])OCC(O[N+](=O)[O-])C(CO[N+](=O)[O-])O[N+](=O)[O-] Chemical compound O=[N+]([O-])OCC(O[N+](=O)[O-])C(CO[N+](=O)[O-])O[N+](=O)[O-] SNFOERUNNSHUGP-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010041899 Stab wound Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- CQFKSGNPWKOHLH-UHFFFAOYSA-N [H]OC1CCOCC2C(O[N+](=O)[O-])CCOCC12 Chemical compound [H]OC1CCOCC2C(O[N+](=O)[O-])CCOCC12 CQFKSGNPWKOHLH-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960003116 amyl nitrite Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 210000001008 atrial appendage Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000994 contrast dye Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 229940064420 dilatrate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- DLOYRBXIOLLBPS-UHFFFAOYSA-N ethyl 7-chloro-1-methyl-4-oxoquinoline-3-carboxylate Chemical compound ClC1=CC=C2C(=O)C(C(=O)OCC)=CN(C)C2=C1 DLOYRBXIOLLBPS-UHFFFAOYSA-N 0.000 description 1
- LDZCUWZFXKDMHH-UHFFFAOYSA-N ethyl 7-fluoro-4-oxo-1h-quinoline-3-carboxylate Chemical compound C1=C(F)C=CC2=C(O)C(C(=O)OCC)=CN=C21 LDZCUWZFXKDMHH-UHFFFAOYSA-N 0.000 description 1
- WVXUVVDDUHEOBM-UHFFFAOYSA-N ethyl 7-oxo-4h-thieno[3,2-b]pyridine-6-carboxylate Chemical compound CCOC(=O)C1=CN=C2C=CSC2=C1O WVXUVVDDUHEOBM-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229940015042 glycopyrrolate Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000005986 heart dysfunction Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229940093221 imdur Drugs 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 229940072673 ismo Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940093268 isordil Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000001000 lipidemic effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004708 n-butylthio group Chemical group C(CCC)S* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229940072991 nitro-bid Drugs 0.000 description 1
- 229940072981 nitro-dur Drugs 0.000 description 1
- 229940073020 nitrol Drugs 0.000 description 1
- 229940073015 nitrostat Drugs 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 150000005299 pyridinones Chemical class 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229940093252 sorbitrate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Definitions
- the present invention relates to compositions and methods for the treatment of cardiovascular disease.
- Cardiovascular disease is the number one cause of death in the United States. Medical Sciences Bulletin, No. 238; p. 1 (1997). While cardiovascular disease presents many different clinical manifestations, hypertension and congestive heart failure (CHF) are major components of this disease state. Uncontrolled hypertension can result in myocardial infarction and stroke. Congestive heart failure, if untreated, is an ultimately fatal disease that kills more than half its victims within five years of initial diagnosis. CHF affects about 3 million people in the United States and about 15 million worldwide. Currently, an estimated 400,000 new cases are diagnosed in the United States each year, and CHF is responsible for about 900,000 hospitalizations a year.
- anti-hypertensive compounds such as: beta-blockers, calcium channel blockers (especially dihydropyrimidines), angiotensin-converting enzyme (ACE) inhibitors, diuretics, and alpha-blockers.
- beta-blockers especially dihydropyrimidines
- ACE angiotensin-converting enzyme
- diuretics diuretics
- alpha-blockers many patients fail to respond to (or tolerate poorly) these compounds.
- cardiovascular disease including, but limited to, hypertension and CHF
- pharmacological intervention for cardiovascular disease including, but limited to, hypertension and CHF
- the present invention provides compositions and methods for the treatment of cardiovascular disease.
- the present invention is particularly suited to the treatment of CHF.
- the methods of the present invention comprise the administration of pharmaceutical compositions to subjects who, in a preferred embodiment, are not concurrently administered nitrites and nitrates.
- the compositions of the present invention comprise quinolinones, including derivatives thereof. Quinolinones are also known as quinolones and oxoquinolines.
- the present invention contemplates halogenated quinolinones (e.g., fluoroquinolinone).
- the quinolinone is a thioquinolinone or a sulphinyl or suphonyl derivatives thereof.
- the halogenated quinolinone is flosequinan [(+ ⁇ )-7-fluoro-1-methyl-3-(methylsulphinyl)-4(1H)-quinolinone]; [7-Fluoro-1-methyl-3-(methylsufinyl)-4(1H)-quinolone].
- an enantiomer [either (+) or ( ⁇ )] of flosequinan is used.
- the present invention contemplates a method, comprising: a) providing: i) a patient presenting at least one symptom of cardiovascular disease, and ii) a purified enantiomer preparation of flosequinan; and b) administering said preparation to said patient (e.g. such that said symptom is reduced).
- a variety of such symptoms of cardiovascular disease are contemplated. It is not intended that the present invention be limited to the reduction of a particular symptom of cardiovascular disease. In a preferred embodiment, the a symptom of hypertension is reduced.
- Hypertension is an abnormal increase of blood pressure in the arteries continuing over a period of time. It occurs when the arterioles, the small blood vessels that branch off from the arteries, become constricted. This constriction of the arterioles makes it difficult for blood to flow which increases pressure against the artery walls.
- a blood pressure reading of approximately 110/60 to 140/90 is considered to be in the normal range.
- the first number (110) is the systolic pressure which measures the blood pressure in the arteries when the heart is contracting and pumping blood.
- the second number (60) is the diastolic pressure which measures the blood pressure in the arteries when the heart is at rest.
- Hypertension adds to the workload of the heart and arteries. Over time, this can lead to heart and blood vessel damage which causes hardening of the arteries, heart failure, stroke, kidneys problems, blindness, and brain damage.
- a symptom of cardiovascular disease comprises a measured blood pressure of approximately 140/90 or higher.
- the diagnosis of said hypertensive blood pressure e.g.
- the present invention contemplates compositions and methods to reduce the symptoms of CHF (also referred to as ‘heart failure’).
- CHF is characterized by an inadequacy of the heart so that, as a pump, it fails to maintain the circulation of blood, such that congestion and edema develop in the tissues of the heart are reduced.
- Symptoms of CHF include, but are not limited to, shortness of breath, pitting edema, an enlarged and tender liver, engorged neck veins, and pulmonary rales in various combinations.
- CHF may be diagnosed based on a medical history and complete physical examination, which may include a blood pressure check, listening to the subject's heart through a stethoscope and taking the subject's pulse.
- a Health Care Provider including, but not limited to, Physicians, Nurse Practitioners, or Physician's Assistants
- a Health Care Provider may order further tests. These test include, but are not limited to, blood tests to assess for anemia and thyroid function, urine tests to measure sugar, an Electrocardiogram (EKG), an exercise stress test, an Echocardiogram, a stress echocardiogram, radionuclide imaging tests (such as a radionuclide ventriculogram).
- More invasive exploratory tests may also be ordered in conjunction with, or instead of the above. These tests include a coronary angiogram, in which a contrast dye is delivered by catheter to the coronary arteries to visualize the blood vessels and identify heart damage or dysfunction.
- the present invention is not limited by the degree of response by the subject. It is expected that the administration of quinolinone enantiomers will reduce the symptoms associated with cardiovascular diseases including, but not limited to, angina pectoris, myocardial infarction, congestive heart failure, cardiomyopathy, hypertension, arterial stenosis, and venous stenosis.
- the enantiomers of flosequinan are administered to reduce the symptoms associated with hypertension.
- the enantiomers of flosequinan are administered to reduce the symptoms of CHF.
- the symptoms of CHF include, but are not limited to, shortness of breath, pitting edema, an enlarged and tender liver, engorged neck veins, and pulmonary rales in various combinations.
- Symptoms are “reduced” when the magnitude (e.g. intensity) or frequency of symptoms is reduced. It is not intended that the present invention be limited only to cases where the symptoms are eliminated. The present invention specifically contemplates treatment such that symptoms are reduced (and the condition of the subject is thereby “improved”), albeit not completely eliminated.
- the subject is a human and the oral dosage of either the (+) or ( ⁇ ) enantiomer of flosequinan is in a single dose per day of up to approximately two hundred milligrams. In another embodiment said dosage is between approximately twenty-five to approximately seventy-five milligrams. In another embodiment, the (+) or the ( ⁇ ) enantiomer is administered in a single oral dose per day of between approximately one hundred and twenty-five and approximately two hundred milligrams. In another embodiment, the administration of said enantiomers of flosequinan comprises three daily doses, before meals, each dose of up to approximately two hundred milligrams per dose. In another embodiment, said daily doses comprise between approximately twenty-five to approximately seventy-five milligrams per dose. In another embodiment, said daily doses comprise between approximately one hundred and twenty-five and approximately two hundred milligrams per dose.
- said enantiomers of flosequinan are introduced orally, cutaneously, by standard injection (e.g. intravenously), or intranasally.
- the method comprises a) providing: i) a patient suffering from symptoms of cardiac disease who is not being administered nitrates or nitrites; and ii) an enantiomer of flosequinan; and b) introducing said enantiomer of flosequinan to said patient such that said symptoms of cardiac disease are reduced.
- said substantially purified enantiomer of flosequinan is a (+) enantiomer.
- said composition is substantially free of the ( ⁇ ) enantiomer of flosequinan.
- the method comprises a) providing: i) a subject suffering from symptoms of cardiovascular disease; and ii) a purified enantiomer preparation of flosequinan, or a pharmaceutically acceptable salt thereof; and b) administering said preparation to the subject such that symptoms are reduced.
- said cardiovascular disease is selected from the group consisting of hypertension, angina pectoris, myocardial infarction, and congestive heart failure.
- Said administering step is selected from the routes consisting of intranasal and respiratory inhalation.
- the method comprises a) providing: i) a subject suffering from symptoms of cardiovascular disease who is not being treated with a drug that causes hypotensive effects, and ii) a purified enantiomer preparation of flosequinan, or a pharmaceutically acceptable salt thereof; and b) administering said preparation to the subject such that such symptoms are reduced.
- the method comprises a) providing: i) a subject suffering from symptoms of cardiovascular disease who is not being treated with a nitrite or nitrate, and ii) a purified enantiomer preparation of flosequinan, or a pharmaceutically acceptable salt thereof; and b) introducing said preparation to the subject such that such symptoms are reduced.
- Said nitrate is selected from the group consisting of glyceryl trinitrate, isosorbide dinitrate, isosorbide-5′-mononitrate, and erythrityl tetranitrate.
- the present invention be limited by the method of introduction of a purified enantiomer preparation of flosequinan, or a pharmaceutically acceptable salt thereof.
- the enantiomer of flosequinan is introduced orally.
- an adult human is provided an oral dosage as a single dose per day of 10 to 200 milligrams.
- enantiomers of flosequinan are introduced cutaneously, by standard injection, intranasally, or through respiratory inhalation.
- the present invention is not limited by the degree of response by the subject. In one embodiment, relief of pain from angina pectoris is sufficient.
- the present invention contemplates a mixture of a purified enantiomer of flosequinan and a carrier, i.e. a mixture comprising lactose.
- the enantiomers recited in the present invention are introduced into said subject by oral administration or cutaneous administration.
- said subject is an adult human and said oral administration comprises up to approximately 200 milligrams of flosequinan.
- the enantiomers of flosequinan recited in the present invention are administered to a subject who has not been treated in the past with a drug that causes hypotensive effects.
- the enantiomers of flosequinan recited in the present invention are administered to a subject who is not being treated with a nitrite or nitrate.
- said nitrate is selected from the group consisting of glyceryl trinitrate, isosorbide dinitrate, isosorbide-5-mononitrate and erythrityl tetranitrate.
- the present invention also contemplates a method, comprising: a) providing: i) a subject suffering from a symptom of a cardiovascular disease selected from the group of hypertension and congestive heart failure and; ii) a purified enantiomer preparation of flosequinan and; b) administering said preparation to said subject under conditions such that said symptom is reduced.
- said purified enantiomer of flosequinan is the (+) enantiomer.
- said purified enantiomer of flosequinan is the ( ⁇ ) enantiomer.
- the enantiomer preparation introduced into said subject by oral or cutaneous administration comprises up to approximately 200 milligrams of flosequinan.
- the present invention also contemplates a purified flosequinan enantiomer preparation comprising a carrier.
- FIG. 1 depicts the chemical structure of a quinolinone (top) and 16 C-7 substituents (bottom).
- FIG. 2 depicts the respective HPLC column retention times and optical rotations of the enantiomers of flosequinan separated by the method provided in Example 2.
- quinolinone refers to chemical compositions comprising quinoline as set forth in the following structure (2-quinolone): as well as other forms of quinolinone, (e.g., isoquinolone):
- derivatives of quinolinone refers to chemical compositions comprising quinolinone with a chemical group attached, including (but not limited to) halogenated quinolinones.
- methylsulphinyl derivatives of quinolinone refers to chemical compositions comprising quinolinone with a methylsulphinyl group attached.
- Examples include flosequinan (7-fluoro-1-methyl-3-(methylsulphinyl)-4(1H)-quinolone; 7-fluoro-1-methyl-3-(methylsufinyl)-4(1H)-quinolinone): and sulfone metabolites of flosequinan: and sulfone metabolites of flosequinan:
- drugs that have hypotensive effects are those drugs which, when administered, cause the subject's end-diastolic blood pressure to be reduced.
- Nitrates are commonly used drugs which have hypotensive effects.
- Nitrates are compounds that contain the —NO 3 — moiety. Nitrates typically used in the clinic are shown in Table 1.
- Nitrites are compounds that contain the —NO 2 — moiety. Nitrites typically used in the clinic are shown in Table 1.
- standard injection refers to the placement of a pharmaceutical composition into a subject (e.g., with a hypodermic needle).
- a pharmaceutical composition e.g., a pharmaceutical composition into a subject (e.g., with a hypodermic needle).
- such injection can be made subcutaneously, intravenously, intramuscularly, intracavemosally, etc.
- oral administration refers to the introduction of a pharmaceutical composition into a subject by way of the oral cavity (e.g., in aqueous liquid or solid form).
- the term “subject” refers to both humans and animals.
- cutaneously refers to the introduction of a pharmaceutical composition into a subject by application to the surface of the skin such that the composition is absorbed into the subject.
- intranasally refers to the introduction of a pharmaceutical composition within the nasal cavity.
- respiratory inhalation refers to the introduction of a pharmaceutical composition within the respiratory tract.
- single dosage refers to a pharmaceutical composition of a formulation that is capable of achieving its intended effect in a single administration or application.
- symptoms of cardiovascular disease refers to any clinical manifestation of a disease state associated with the heart and vasculature.
- said clinical manifestation include: angina pectoris, myocardial infarction, congestive heart failure, cardiomyopathy, hypertension, arterial stenosis, and venous stenosis.
- the present invention specifically contemplates treatment such that symptoms are reduced (and the condition of the subject is thereby “improved”), albeit not completely eliminated.
- “congestive heart failure” is a specific cardiovascular disease which is characterized, but not limited to, the following symptoms: shortness of breath, pitting edema, an enlarged and tender liver, engorged neck veins, and pulmonary rales in various combinations.
- lower alkyl denote such groups containing 1-8 carbon atoms, especially 2-4 carbon atoms for lower alkanoyl and 1-4 carbon atoms for the other groups.
- Examples of such groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-heptyl, n-octyl, methoxy, ethoxy, propoxy, n-butoxy, isobutoxy, acetyl, propionyl, butyryl, methylthio, ethylthio, propylthio and n-butylthio.
- active compound denotes a pyridinone compound of general formula I (as illustrated and described below in the section entitled “Other Compounds Useful In The Treatment of Cardiovascular Disease”), or a quinolinone or quinolinone derivative as illustrated and described above.
- diastereoisomers refers to stereoisomers that are not mirror images of each other.
- enantiomer refers to stereoisomers of molecules that are non-superimposable mirror images of each other. Enantiomers have identical physical properties, such as melting points and boiling points, and also have identical spectroscopic properties. Enantiomers differ from each other with respect to their interaction with plane-polarized light and with respect to their biological activity.
- stereoisomer refers to compounds that have their atoms connected in the same order but differ in the arrangement of their atoms in space. (e.g. cis-2-butane and trans-2-butane).
- racemic mixture refers to a mixture of the two enantiomers of one compound.
- An ideal racemic mixture is one wherein there is a 50:50 mixture of both enantiomers of a compound such that the optical rotation of the (+) enantiomer cancels out the optical rotation of the ( ⁇ ) enantiomer.
- purified enantiomer and “purified enantiomer preparation” are meant to indicate a preparation (e.g. derived from a racemic mixture or synthesized de novo) wherein one enantiomer has been enriched over the other, and more preferably, wherein the other enantiomer represents less than 10%, and more preferably less than 5%, and still more preferably, less than 2% of the preparation.
- salts or “a pharmaceutically acceptable salt thereof” refer to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids and bases and organic acids and bases. Since the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids.
- Suitable pharmaceutically acceptable acid addition salts for the compound of the present invention include acetic, benzenesulfonic (besylate), benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic, and the like.
- Preferred acid addition salts are the chloride and sulfate salts.
- the present invention relates to methods for the treatment of cardiovascular disease.
- the present invention contemplates compositions and methods for the treatment of CHF and hypertension. These compositions comprise quinolinones, including derivatives and enantiomers thereof. A variety of quinolinone derivatives are shown in FIG. 1 . Methods for producing antibiotic derivatives of a particular quinolone carboxylic acid skeleton are provided in U.S. Pat. No. 4,623,650 to Gilligan et al., hereby incorporated by reference.
- the present invention is not limited by the nature of the derivatives, in one embodiment, the present invention encompasses the use of a variety of quinolinone derivatives (e.g., 5-bromoquinoline, 5-nitroisoquinoline, 8-nitroisoquinoline and 1-methylisoquinoline).
- quinolinone derivatives e.g., 5-bromoquinoline, 5-nitroisoquinoline, 8-nitroisoquinoline and 1-methylisoquinoline.
- One skilled in the art can readily produce such derivatives as set forth in McMurry, Organic Chemistry, 2 nd Ed ., Brooks/Cole Publishing, Belmont, CA (1988), pages 1044-1045 and 1076.
- the present invention contemplates the use of methylthio and methylsulplinyl derivatives of quinolinone.
- the methylsulphinyl derivative is flosequinan (whether as a racemic mixture or as a purified enantiomer).
- the present invention contemplates compositions and methods for the treatment of CHF and hypertension in subjects who are not concurrently being treated with nitrites or nitrates.
- the present invention contemplates the administration of the enantiomers of flosequinan as a methods of treating CHF and hypertension.
- the optically active derivatives and metabolites of flosequinan are also contemplated.
- a purified enantiomer preparation of flosequinan is administered. It is contemplated that an enantiomer of flosequinan be administered cutaneously, by standard injection, intranasally, or through respiratory inhalation. It is not intended that the methods of the present invention be limited to the mode of administration of an enantiomer of flosequinan.
- Suitable animal models include, but are not limited to, species including rodents, non-human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, and aves.
- female rats (weight range 180-240 g) of the Aoki-Okamoto strain of spontaneously hypertensive can be used.
- the rats are divided into groups of four and will be fasted overnight before administration of either the (+) or ( ⁇ ) enantiomer of flosequinan.
- Blood pressure will be determined in the following way.
- the rats are placed in a restraining cage, maintained at 38° C., with their tails protruding through holes in the cage. After 30 minutes in the cage, blood pressure will be measured using an inflatable cuff placed round the base of the tail and arterial pulsations will be monitored with a pneumatic pulse transducer.
- a limb or a phalanx as a site to monitor blood pressure.
- a pressure, greater than the expected blood pressure, will be applied to the cuff and this pressure will be slowly reduced.
- the pressure in the cuff at which arterial pulsations reappears will be recorded as the blood pressure.
- the rats will be removed from the cage and each group will be orally administered a given dose of either the (+) or ( ⁇ ) enantiomer of flosequinan.
- blood pressure will be measured at 1.5 and 5.0 hours after dosing.
- a effective dosage will be defined as follows.
- Either the (+) or ( ⁇ ) enantiomer of flosequinan will be tested initially at a given dose level (for example 90 mg/kg). If the compound is considered sufficiently active (giving a reduction of blood pressure equal to or greater than of approximately 15% after correction) it will be retested at a lower dose level, for example 30 mg/kg. By testing at successively lower dose levels, a threshold antihypertensive dose (dose giving a reduction of blood pressure of between 5 and 15% after correction) will be determined. Compounds which are inactive at a particular dose level and which produce a reduction of blood pressure equal to or greater than 15% after correction at the next highest dose level will be designated as having a threshold antihypertensive dose within the range covered by the two dose levels.
- a threshold antihypertensive dose dose giving a reduction of blood pressure of between 5 and 15% after correction
- the above described protocol is suited it a variety of hypertensive and normotensive animal models.
- a normotensive marmoset monkey will be used.
- VAPs subcutaneous vascular access ports
- a solid-state micromanometer (Konigsberg Instruments) will be introduced via a stab wound in the ventricular apex and secured with a purse-string suture.
- a unipolar pacing lead will be sutured to the posterior wall of the LV and connected to a programmable pacemaker (Medtronic, Model Minix 8340) that will be situated subcutaneously over the left chest wall.
- a programmable pacemaker Medtronic, Model Minix 8340
- Internal electrocardiogram (ECG) leads will be sutured to the chest wall. All catheters and wires will be tunneled subcutaneously to the dorsal midline below the scapula.
- Transdermal titanium skin buttons (Konigsberg Instruments) attached to the wires from the LV pressure transducer and ECG leads will be secured along the midline, while the catheter VAPs will be situated in subcutaneous pockets. The chest will be closed in layers and negative intrapleural pressure restored via a temporary chest tube.
- Antibiotics (Cefazolin, 30 mg/kg) will be administered subcutaneously prior to surgery and postoperatively for 10 days (30 mg/kg bid).
- Buprenorphine (0.01 mg/kg sq) will be administered for analgesia immediately after surgery and as needed the first postoperative week. All monkeys will be allowed to recover for a minimum of 2 weeks after surgery and were conditioned to sit in upright/reclining primate restraint chairs prior to commencement of experimental investigations.
- Arterial blood pressure will be measured by inserting into the aortic VAP a saline-filled needle-tipped catheter, the other end of which was connected to a Statham P23 XL pressure transducer.
- Intravenous agents will be delivered via a similar catheter extension set inserted into the right atrial VAP.
- Left ventricular pressure (LVP) will be measured via the Konigsberg micromanometer and will be cross-calibrated with the aortic pressure signal, and the transthoracic ECG will be measured using a Gould ECG/Biotach amplifier (Gould Instrument Systems).
- All physiological signals will be sampled at 500 Hz using a computerized digital data acquisition system (Po-Ne-Mah, Gould Instrument Systems), while being simultaneously recorded on digital audio tape (Model RD 111T, Teac) and displayed on an MT 95000 eight-channel thermal-array recorder (Astro-Med).
- HR heart rate
- MAP mean arterial blood pressure
- LVSP left ventricular systolic and end-diastolic blood pressures
- LVEDP peak positive rate of change in LVP (+dP/dt max )
- LV dimensions will be recorded with the primates under ketamine sedation using M-mode echocardiographic imaging (Hewlett Packard Sons 100CF) of the LV via a left transthoracic approach. Images will be recorded on VHS tape for subsequent calculation of LV fractional shortening and wall thickening percentage (WT) from the short axis and wall thickness dimensions.
- WT fractional shortening and wall thickening percentage
- end-diastolic dimensions will be defined as occurring at the peak of the R-wave, while end-systole will be associated with the peak of the T-wave.
- Systolic WT will be then calculated as the difference between end-systolic and end-diastolic dimensions and is expressed as percent change from end-diastolic thickness [(EST ⁇ EDT)/EDT] ⁇ 100.
- the present invention be limited by the species of the animal model used to evaluate the efficacy of a given compound as potential CHF therapeutic.
- the above described protocol is suited it a variety of hypertensive and normotensive animal models.
- a normotensive marmoset monkey will be used.
- compositions utilized in the methods of the present invention comprise purified enantiomers of flosequinan, including derivatives thereof.
- present invention is not limited by a specific means of producing enantiomers of flosequinan, methods of producing a racemic mixture of flosequinan (and methylsuphinyl/methylthio derivatives of quinolinone) are set forth in U.S. Pat. Nos. 5,079,264 and 5,011,931 to MacLean et al., hereby incorporated by reference.
- the present invention contemplates the administration of a purified enantiomer of flosequinan.
- Many organic compounds, including flosequinan exist in optically active forms (i.e., they have the ability to rotate the plane of plane-polarized light).
- the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral center(s).
- the prefixes d and l or (+) and ( ⁇ ) are employed to designate the sign of rotation of plane-polarized light by the compound, with ( ⁇ ) or l meaning that the compound is levorotatory (rotates to the left).
- a compound prefixed with (+) or d is dextrorotatory (rotates to the right).
- the present invention is not limited by any specific means of resolving the (+) and ( ⁇ ) enantiomers of flosequinan to obtain a substantially purified enantiomer of flosequinan.
- the enantiomers were resolved according to the methods in Example 2.
- the enantiomers of flosequinan can function as a vasodilator. This vasodilation decreases the total peripheral resistance offered by the vasculature, thereby, decreasing blood pressure.
- Flosequinan has also been reported to be a selective inhibitor of phosphodiesterase III (PDE3). (See Gristwood et al., Br. J. Pharmacol., 105: 985 (1992); Frodsham et al., Eur. J. Pharmacol. 211: 383 (1992)). Inhibitors of PDE3 cause vasodilation leading to a concomitant reduction in arterial blood pressure. See Shiraishi et al., Br. J. Pharmacol., 123: 869-878 (1998).
- the (+) and ( ⁇ ) enantiomers of flosequinan were subjected to biochemical assays to determine their respective percent inhibition of PDE3.
- the (+) enantiomer of flosequinan has an eight-fold increase in PDE3 inhibition as compared to that of the ( ⁇ ) enantiomer of flosequinan at the same molar concentration.
- the (+) enantiomer of flosequinan exhibited greater inhibition of PDE3 than a racemic mixture of flosequinan at the same molar concentration. Further data concerning this is provided in Example 3.
- a 100 ⁇ M mixture of the (+) and ( ⁇ ) enantiomers of flosequinan were subjected to biochemical assays to determine their respective percent inhibition of PDE6 as compared to that of sildenafil citrate at a concentration of 1 ⁇ M.
- the mixture of the (+) and ( ⁇ ) enantiomers of flosequinan exhibited approximately half as much inhibition of PDE6 as compared to that of a 100-fold lower molar concentration of sildenafil citrate. Further data concerning this is provided in Example 1.
- an adult human suffering from cardiovascular disease is readily made by a person skilled in the art using a number of readily available diagnostic procedures.
- an adult human suffering from cardiovascular disease can first be given a physical examination with particular attention to possible blood pressure or heart rhythm pathology, whereby many anatomical electophysiological cardiovascular abnormalities can be detected.
- Tests to determine hypertension may be performed by doppler investigation of the venous blood return system sufficiency. Blood pressures can be determined by a number of standard techniques.
- Tests to determine myocardial infarction include detecting aberrations in blood enzymes. Following a myocardial infarction the damaged heart cells release of lactate dehydrogenase (LDH) subtypes result in circulating ratios that are not normally observed in a healthy person.
- LDH lactate dehydrogenase
- Test to determine angina pectoris include testing procedures as with myocardial infarction, only with the appearance of normal LDH subtype ratios.
- Test to determine congestive heart failure include comparisons of blood pressures, cardiac output and stroke volume measurement. Congestive heart failure is a debilitating progressive condition that is fatal if immediate action is not taken.
- the (+) enantiomer of flosequinan is provided together with physiologically tolerable liquid, gel or solid carriers, diluents, adjutants and excipients.
- enantiomers of flosequinan may be used together with other chemotherapeutic agents.
- formulations may also contain such normally employed additives as binders, fillers, carriers, preservatives, stabilizing agents, emulsifiers, buffers and excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions typically contain 1%-95% of active ingredient, preferably 2%-70%.
- the present invention is not limited by the method of introduction of the compound to the body.
- the present invention contemplates administering cutaneously, orally, or by standard injection (e.g. intravenous).
- the present invention also contemplates administering the enantiomers of flosequinan to the subject intranasally or through respiratory inhalation.
- Formulations suitable for intranasal administration include ointments, creams, lotions, pastes, gels, sprays, aerosols, oils and other pharmaceutical carriers which accomplish direct contact between an enantiomer of flosequinan or a pharmaceutical composition comprising an enantiomer of flosequinan and the nasal cavity.
- Examples of pharmaceutical compositions administered intranasally are described in U.S. Pat. Nos. 5,393,773 and 5,554,639 to Craig et al.; and 5,801,161 to Merkus, all hereby incorporated by reference.
- Formulations suitable for respiratory inhalation include ointments, creams, lotions, pastes, gels, sprays, aerosols, oils and other pharmaceutical carriers which accomplish direct contact between an enantiomer of flosequinan or a pharmaceutical composition comprising an enantiomer of flosequinan and the respiratory tract.
- Examples of pharmaceutical compositions administered through respiratory inhalation are described in U.S. Pat. No. 4,552,891 to Hu et al.; U.S. Pat. No. 5,869,479 to Kreutner et al., and U.S. Pat. No. 5,864,037 to Chasis et al., all hereby incorporated by reference.
- intranasal administration and respiratory inhalation are the preferred modes of administration due to the ease of administration and faster onset of therapeutic activity. It is contemplated that intranasal administration and respiratory inhalation are advantageous as they may allow a smaller effective dosage to be administered than would be possible with the oral route of administration.
- a preferred mode of administration comprises administration to the lung. Intrapulmonary delivery of pharmacologic agents to subjects can be accomplished via aerosolization. Alternatively, the agent may be administered to the lung through a bronchoscope. Of course, the therapeutic agents may be investigated for their efficacy via other routes of administration, including parenteral administration.
- Oral administration of an enantiomer of flosequinan is an effective mode of administration, with a mean absolute bioavailability of 72% following a single dose of fifty milligrams. Peak plasma concentrations of an enantiomer of flosequinan are observed 1-2 hours following oral administration, while peak metabolite plasma levels are observed about seven hours following oral dosage.
- the dosage is a single dosage per day of 10 milligrams, while in another preferred embodiment the dosage is a single dosage per day of 25 milligrams, while in another preferred embodiment the dosage is a single dosage per day of 50 milligrams, while in yet another preferred embodiment the dosage is a single dosage per day of 75 milligrams.
- the dosage is a single dosage per day of approximately 125 milligrams and in another preferred embodiment, the dosage is a single dosage per day of approximately 150 milligrams. In another preferred embodiment, the dosage is a single dosage per day of approximately 200 milligrams. Multiple dosage is also contemplated.
- Flosequinan and its enantiomers are water soluble and soluble in many organic solvents.
- aqueous and organic solution of an enantiomer of flosequinan for oral administration is contemplated.
- an enantiomer of flosequinan can be associated with a solid pharmaceutical carrier for solid oral administration (i.e., in pill form).
- the inactive ingredients include croscarmellose sodium, hydroxypropyl methylcellulose, lactose, magnesium stearate, methocel E5, microcrystalline cellulose, povidine, propylene glycol and titanium dioxide.
- the enantiomers of flosequinan may also be administered cutaneously in a carrier adapted for topical administration.
- a carrier adapted for topical administration.
- Such carriers include creams, ointments, lotions, pastes, jellies, sprays, aerosols, bath oils, or other pharmaceutical carriers which accomplish direct contact between an enantiomer of flosequinan and the pore of the skin.
- pharmaceutical preparations may comprise from about 0.001% to about 10%, and preferably from about 0.01 to 5% by w/w of the active compound (e.g., an enantiomer of flosequinan) in a suitable carrier.
- an appropriate solvent such as ethanol or DMSO (dimethylsulfoxide), and the like, to facilitate incorporation into a pharmaceutical preparation.
- injection of an enantimer of flosequinan can be carried out by any conventional injection means (e.g., employing an hypodermic syringe and needle or a similar device such as the NovolinPen sold by Squibb-Novo, Inc., Princeton, N.J., USA). This injection may be by the subject injecting him or herself or by another person injecting the subject.
- Flosequinan and its enantiomers can be introduced by injection in a physiologically acceptable composition.
- Such compositions are aqueous solutions that are physiologically acceptable for administration by injection.
- the physiologically acceptable carrier is selected such that it is not painful or irritating upon injection.
- the physiologically acceptable compositions will preferably be sterile at the time of administration by injection.
- physiologically acceptable compositions for use in the methods is physiological saline or phosphate buffered saline, in which the enantiomers of flosequinan are dissolved or suspended, such that the resulting composition is suitable for injection.
- a physiologically acceptable composition can also include a non-irritant preservative, such as, e.g., benzalkonium chloride at 0.05% (w/v) to 0./2% (w/v).
- non-toxic salts of VIP, PHM and ⁇ -adrenergic blockers that can be employed in a physiologically acceptable composition for use in the methods herein, including, among others, the chloride, bromide, acetate, sulfate, and mesylate salts.
- the present invention is not limited to the method of injecting the enantiomers of flosequinan, in the preferred embodiment, it is injected with a standard syringe.
- One skilled in the art would be capable of injecting the enantiomers of flosequinan with a carrier as described above.
- the present invention provides methods for the treatment human cardiovascular disease with the enantiomers of flosequinan (or a formulation comprising the enantiomers of flosequinan).
- the invention is further directed to pyridinone compounds with therapeutic activity, and to compositions containing such compounds, wherein the compounds have the general formula I:
- R 1 is hydrogen, lower alkyl optionally substituted by hydroxy or C 1-4 alkoxycarbonyl, allyl, propynyl or phenyl-lower alkyl in which the phenyl ring is optionally substituted by 1 or 2 C 1-4 alkoxy groups;
- R 2 is hydrogen or lower alkyl;
- R 3 is (X) m —S(O) n R 4 , COR 5 , SR 6 , or S(OH) (O)NR 7 , wherein m is 0 or 1, n is 0, 1, or 2, X is oxygen or lower alkylene, R 4 is C 1-4 alkyl, R 5 is hydroxyl, lower alkyl carbonyl, amino, or lower alkyl amino, and R 6 and R 7 are lower alkyl; and ring A represents an optionally substituted phenyl ring
- the compounds of the general formula I have been found to have antihypertensive activity and cardiac activity in warm-blooded animals.
- the compounds, methods of making the compounds, antihypertensive and cardiac therapeutic compositions of the compounds, and methods for treating hypertension and heart failure using the compounds are described in U.S. Pat. No. 4,302,460, U.S. Pat. No. 4,522,884, U.S. Pat. No. 4,855,291, U.S. Pat. No. 4,877,793, U.S. Pat. No. 4,710,506, U.S. Pat. No. 4,772,614 and U.S. Pat. No. 4,997,840, the disclosures of which patents are expressly incorporated herein, in their entirety, by reference.
- the invention provides pharmaceutical compositions comprising compounds of the general formula I, and methods of using the compositions to treat subjects with symptoms of cardiovascular disease, such that said symptoms are reduced.
- the invention is not limited by the particular nature of the pharmaceutical composition, or by the method of introduction of the active or therapeutic compound to the body. All of the treatment methods and compositions contemplated above are also contemplated here for compounds of formula I.
- the active ingredient in the compositions is preferably administered in unit dosage form.
- tablets and capsules may conveniently contain a unit dosage of the active compound of 1-500 mg/kg, more preferably 5-100 mg/kg and still more preferably 5-50 mg/kg.
- the compounds of formula I may contain one or more asymmetric centers and, therefore, can exist as enantiomers or diastereoisomers. Furthermore, certain compounds of formula I containing alkenyl groups may exist as cis-isomers or transisomers. In each case, the invention includes both mixtures and separate individual isomers. The compounds of formula I may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers.
- Preferred compounds of the general formula I for use in the pharmaceutical compositions and methods of the invention are compounds having the general formulas II and III: wherein R 1 , R 3 , R 8 , R 9 , R 10 , and R 11 are defined as above.
- R 3 is (X) m —S(O) n R 4 , COR 5 , SR 6 , or S(OH) (O)NR 7 ;
- Preferred embodiments include compounds of formula IIA wherein R 1 and R 2 are methyl, R 9 is hydrogen and R 10 is halo, lower alkyl or trifluoromethyl. More preferably, R 10 is halo or C 1 -C 4 alkyl. In yet another preferred embodiment, R 9 is 6-lower alkoxy and R 10 is halo or lower alkoxy. In a further preferred embodiment, R 9 is 6-halo and R 10 is lower alkoxy. In another preferred embodiment, R 10 is C 1 -C 4 alkyl.
- preferred embodiments include compounds of formula IIB, IIC, IID, IIE, IIF, IIIA and IIIB as follows:
- Preferred compounds of formula IIB are those in which m is 1, n is 2, and X is oxygen.
- Preferred compounds of formula IIC include those in which m is 0, n is 1 or 2, and R 4 is methyl.
- Preferred compounds of formula IID include those in which R 5 is amino or lower alkyl amino.
- Preferred compounds of formula IIE include those in which R 6 is methyl.
- Preferred compounds of formula IIF include those in which R 7 is methyl.
- Preferred compounds of formula IIIA include those in which n is 1 and R 4 is methyl.
- Preferred compounds of formula IIIB include those in which R 5 is amino or lower alkyl amino.
- Specific preferred compounds of these formulae include: 1-methyl-3-methylsulphinyl-4-quinolone, 7-fluoro-1-methyl-4-oxo-1,4-dihydroquinolone-3-carboxamide, 4-methyl-7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide, 4-methyl-6-methylsulphinyl-7(4H)-thieno[3,2-b]pyridinone, 7-chloro-1-methyl-3-methylsulphamoyl-4-quinolone, 1-methyl-4-oxo-1,4-dihydroquinol-3-yl methanesulphonate, 7-chloro-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide, 7-fluoro-1-methyl-3-methylsulphonyl-4-quinolone, or 7-fluoro-1-methyl-3-methylthio-4-quinolone, or pharmaceutically acceptable salts thereof.
- a biochemical assay was performed to test the percentage of phosphodiesterase 6 (PDE6) inhibition of various molar concentrations of sildenafil citrate (Viagra) as compared to that of a 100 ⁇ M concentration of a racemic mixture of flosequinan as follows.
- PDE6 phosphodiesterase 6
- PDE6 partially purified from bovine retinal rod and activated by trypsin was used.
- Viagra at molar concentrations of 0.3 ⁇ M, 1.0 ⁇ M, and 3.0 ⁇ M, and a 100 ⁇ M racemic mixture of flosequinan were incubated with 0.2 ⁇ g/ml active PDE6 and 100 ⁇ M cGMP containing 0.1 ⁇ M [ 3 H]cGMP in Tris buffer pH 7.5 for 20 minutes at 30° C.
- Each reaction was terminated by raising the temperature to 100° C. for 2 minutes.
- the resulting GMP was converted to guanosine by addition of 10 mg/ml snake venom nucleotidase and further incubated at 30° C. for 10 minutes.
- Unhydrolyzed cGMP was bound to AGI-X2 resin, and [ 3 H]guanosine remaining in the aqueous phase was quantitated by scintillation counting.
- the enantiomers of flosequinan were resolved by high-performance liquid chromatography (HPLC) as follows.
- HPLC high-performance liquid chromatography
- a 5.0 g sample of a racemic mixture of flosequinan was resolved over a 10 cm ID ⁇ 50 cm L CHIRALCEL OD HPLC column (Chiral Technologies, Exton, PA) at 25° C. and with a flow rate of 1.0 ml/minute such that the column pressure was 37 bar.
- the mobile phase employed was 100% methanol and the detection of the mixture was performed at 270 nm.
- the ( ⁇ ) enantiomer had a retention time of 3.13 minutes, while the (+) enantiomer had a retention time of 4.40 minutes.
- a total of 2.1 g of the ( ⁇ ) enantiomer having an optical purity greater than 99% was produced.
- a total of 2.3 g of the (+) enantiomer having an optical purity greater than 99% was produced. (See, FIG. 2
- a racemic mixture of flosequinan and the (+) and ( ⁇ ) enantiomers of flosequinan were subjected to biochemical enzyme assays to determine their respective percent inhibition of a variety of phosphodiesterases (PDEI-PDE6).
- the reaction conditions for each PDE assay were as follows.
- PDE1 partially purified from bovine heart was used. A racemic mixture of flosequinan, and each enantiomer of flosequinan, all at a molar concentration of 100 ⁇ M, were independently incubated with 13 ⁇ g PDE1 enzyme, 1.0 ⁇ M [ 3 H]cAMP and CaCl 2 /calmodulin in Tris buffer pH 7.5 for 20 minutes at 30° C. The reaction was terminated by boiling for 2 minutes, and the resulting AMP was converted to adenosine by addition of 10 mg/ml snake venom nucleotidase and further incubation at 30° C. for 10 minutes. Unhydrolyzed cAMP was bound to AGI-X2 resin, and the remaining [ 3 H]adenosine in the aqueous phase was quantitated by scintillation counting.
- PDE2 partially purified from human platelets was used. A racemic mixture of flosequinan, and each enantiomer of flosequinan, all at a molar concentration of 100 ⁇ M, were independently incubated with 23 ⁇ g PDE2 enzyme, 25 ⁇ M cAMP containing 0.05 ⁇ M [ 3 H]cAMP in Tris buffer pH 7.5 for 20 minutes at 30° C. The reaction was terminated by boiling for 2 minutes, and the resulting AMP was converted to adenosine by addition of 10 mg/ml snake venom nucleotidase and further incubation at 30° C. for 10 minutes. Unhydrolyzed cAMP was bound to AGI-X2 resin, and the remaining [ 3 H]adenosine in the aqueous phase was quantitated by scintillation counting.
- PDE3 partially purified from human platelets was used. A racemic mixture of flosequinan, and each enantiomer of flosequinan, all at a molar concentration of 100 ⁇ M, were independently incubated with 13 ⁇ g PDE3 enzyme and 1 ⁇ M cAMP containing 0.01 ⁇ M [ 3 H] cAMP in Tris buffer pH 7.5 for 20 minutes at 30° C. The reaction was terminated by boiling for 2 minutes, and the resulting AMP was converted to adenosine by addition of 10 mg/ml snake venom nucleotidase and further incubation at 30° C. for 10 minutes. Unhydrolyzed cAMP was bound to AGI-X2 resin, and the remaining [ 3 H]adenosine in the aqueous phase was quantitated by scintillation counting.
- PDE4 PDE4 partially purified from human U-937 pronocytic cells was used. A racemic mixture of flosequinan, and each enantiomer of flosequinan, all at a molar concentration of 100 ⁇ M, were independently incubated with 20 ⁇ g PDE4 enzyme and 1 ⁇ M cAMP containing 0.01 ⁇ M [ 3 H]cAMP in Tris buffer pH 7.5 for 20 minutes at 30° C. The reaction was terminated by boiling for 2 minutes, and the resulting AMP was converted to adenosine by addition of 10 mg/ml snake venom nucleotidase and further incubation at 30° C. for 10 minutes. Unhydrolyzed cAMP was bound to AGI-X2 resin, and the remaining [ 3 H]adenosine in the aqueous phase was quantitated by scintillation counting.
- PDE5 partially purified from human platelets was used. A racemic mixture of flosequinan, and each enantiomer of flosequinan, all at a molar concentration of 100 ⁇ M, were independently incubated with 120 ⁇ g PDE5 enzyme and 1 ⁇ M cGMP containing 0.01 ⁇ M [ 3 H]cGMP in Tris buffer pH 7.5 for 20 minutes at 30° C. The reaction was terminated by boiling for 2 minutes, and the resulting GMP was converted to guanosine by addition of 10 mg/ml snake venom nucleotidase and further incubation at 30° C. for 10 minutes. Unhydrolyzed cGMP was bound to AGI-X2 resin, and the remaining [ 3 H]guanosine in the aqueous phase was quantitated by scintillation counting.
- PDE6 PDE6 partially purified from bovine retinal rod and activated by trypsin was used. A racemic mixture of flosequinan, and each enantiomer of flosequinan, all at a molar concentration of 100 ⁇ M, were independently incubated with 0.2 ⁇ g/ml active PDE6 and 100 ⁇ M cGMP containing 0.1 ⁇ M [ 3 H]cGMP in Tris buffer pH 7.5 for 20 minutes at 30° C. Each reaction was terminated by boiling for 2 minutes. The resulting GMP was converted to guanosine by addition of 10 mg/mil snake venom nucleotidase, and further incubated at 30° C. for 10 minutes. Unhydrolyzed cGMP was bound to AGI-X2 resin, and [ 3 H]guanosine remaining in the aqueous phase was quantitated by scintillation counting.
- a mixture of ethyl 7-chloro-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (5.0 g) and aqueous ammonia (specific gravity 0.88, 100 ml) can be stirred and heated on a steam bath for 3.5 hours. More aqueous ammonia (100 ml) can be added and heating continued for a further 21 hours. The mixture can be cooled in ice. The solid product can be collected by filtration and dried to give the compound 7-chloro-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide, m.p. >240° C.
- the present invention provides methods of treatment of symptoms of cardiovascular disease with pharmaceutical agents.
- quinolinone enantiomers are administered therapeutically to subjects having such symptoms.
Abstract
The present invention is directed to compositions and methods for treating cardiovascular disease. In a preferred embodiment, the present invention contemplates using the enantiomers of flosequinan (and formulations comprising flosequinan) in subjects not concurrently treated with nitrites or nitrates.
Description
- The present invention relates to compositions and methods for the treatment of cardiovascular disease.
- Cardiovascular disease is the number one cause of death in the United States. Medical Sciences Bulletin, No. 238; p. 1 (1997). While cardiovascular disease presents many different clinical manifestations, hypertension and congestive heart failure (CHF) are major components of this disease state. Uncontrolled hypertension can result in myocardial infarction and stroke. Congestive heart failure, if untreated, is an ultimately fatal disease that kills more than half its victims within five years of initial diagnosis. CHF affects about 3 million people in the United States and about 15 million worldwide. Currently, an estimated 400,000 new cases are diagnosed in the United States each year, and CHF is responsible for about 900,000 hospitalizations a year.
- The current treatment approaches involve anti-hypertensive compounds, such as: beta-blockers, calcium channel blockers (especially dihydropyrimidines), angiotensin-converting enzyme (ACE) inhibitors, diuretics, and alpha-blockers. However, many patients fail to respond to (or tolerate poorly) these compounds.
- For example, many patients do not respond to diuretics (with or without digitalis). Moreover, many patients cannot tolerate (or respond poorly to) ACE inhibitors. In addition the use of beta blockers has been associated with loss of glycemic control. Studies on the Glycemic and Lipidemic Effect of Atenolol and Propranolol in Normal and Diabetic Rats, (Abstract), Arzneimittelforschung, 44(4): 496-501 (April, 1994).
- What is needed, therefore, is an pharmacological intervention for cardiovascular disease (including, but limited to, hypertension and CHF) that is less disruptive to the patient and is be better tolerated in comparison to existing treatment modalities.
- The present invention provides compositions and methods for the treatment of cardiovascular disease. In a preferred embodiment, the present invention is particularly suited to the treatment of CHF. The methods of the present invention comprise the administration of pharmaceutical compositions to subjects who, in a preferred embodiment, are not concurrently administered nitrites and nitrates. Specifically, the compositions of the present invention comprise quinolinones, including derivatives thereof. Quinolinones are also known as quinolones and oxoquinolines.
- In another embodiment, the present invention contemplates halogenated quinolinones (e.g., fluoroquinolinone). In a preferred embodiment, the quinolinone is a thioquinolinone or a sulphinyl or suphonyl derivatives thereof. In one embodiment, the halogenated quinolinone is flosequinan [(+−)-7-fluoro-1-methyl-3-(methylsulphinyl)-4(1H)-quinolinone]; [7-Fluoro-1-methyl-3-(methylsufinyl)-4(1H)-quinolone]. In a preferred embodiment, an enantiomer [either (+) or (−)] of flosequinan is used.
- In one embodiment, the present invention contemplates a method, comprising: a) providing: i) a patient presenting at least one symptom of cardiovascular disease, and ii) a purified enantiomer preparation of flosequinan; and b) administering said preparation to said patient (e.g. such that said symptom is reduced). A variety of such symptoms of cardiovascular disease are contemplated. It is not intended that the present invention be limited to the reduction of a particular symptom of cardiovascular disease. In a preferred embodiment, the a symptom of hypertension is reduced.
- Hypertension is an abnormal increase of blood pressure in the arteries continuing over a period of time. It occurs when the arterioles, the small blood vessels that branch off from the arteries, become constricted. This constriction of the arterioles makes it difficult for blood to flow which increases pressure against the artery walls.
- A blood pressure reading of approximately 110/60 to 140/90 is considered to be in the normal range. The first number (110) is the systolic pressure which measures the blood pressure in the arteries when the heart is contracting and pumping blood. The second number (60) is the diastolic pressure which measures the blood pressure in the arteries when the heart is at rest. Hypertension adds to the workload of the heart and arteries. Over time, this can lead to heart and blood vessel damage which causes hardening of the arteries, heart failure, stroke, kidneys problems, blindness, and brain damage. In one embodiment of the present invention, a symptom of cardiovascular disease comprises a measured blood pressure of approximately 140/90 or higher. In a preferred embodiment, the diagnosis of said hypertensive blood pressure (e.g. approximately 140/90 or higher) is confirmed by a plurality of measurements of approximately 140/90 or higher spaced over the period of at least two weeks. It is not intended that the present invention be limited by the means by which blood pressure is measured. Moreover, additional symptoms of hypertension also include, but are not limited to, tiredness, confusion, nausea, vomiting, anxiety, excessive perspiration, muscle tremor, chest pain, nosebleed, and buzzing in the ears.
- In another embodiment, the present invention contemplates compositions and methods to reduce the symptoms of CHF (also referred to as ‘heart failure’). CHF is characterized by an inadequacy of the heart so that, as a pump, it fails to maintain the circulation of blood, such that congestion and edema develop in the tissues of the heart are reduced. Symptoms of CHF include, but are not limited to, shortness of breath, pitting edema, an enlarged and tender liver, engorged neck veins, and pulmonary rales in various combinations.
- It is not intended that the present invention be limited by the method by which CHF is diagnosed. CHF may be diagnosed based on a medical history and complete physical examination, which may include a blood pressure check, listening to the subject's heart through a stethoscope and taking the subject's pulse. At physical exam a Health Care Provider (including, but not limited to, Physicians, Nurse Practitioners, or Physician's Assistants) may look for the symptoms of CHF (as listed above).
- If a Health Care Provider does not find enough symptoms to make a diagnosis, but is still suspicious that the subject has CHF, then her or she may order further tests. These test include, but are not limited to, blood tests to assess for anemia and thyroid function, urine tests to measure sugar, an Electrocardiogram (EKG), an exercise stress test, an Echocardiogram, a stress echocardiogram, radionuclide imaging tests (such as a radionuclide ventriculogram).
- More invasive exploratory tests may also be ordered in conjunction with, or instead of the above. These tests include a coronary angiogram, in which a contrast dye is delivered by catheter to the coronary arteries to visualize the blood vessels and identify heart damage or dysfunction.
- The present invention is not limited by the degree of response by the subject. It is expected that the administration of quinolinone enantiomers will reduce the symptoms associated with cardiovascular diseases including, but not limited to, angina pectoris, myocardial infarction, congestive heart failure, cardiomyopathy, hypertension, arterial stenosis, and venous stenosis. In a preferred embodiment, the enantiomers of flosequinan are administered to reduce the symptoms associated with hypertension.
- In another preferred embodiment, the enantiomers of flosequinan are administered to reduce the symptoms of CHF. The symptoms of CHF include, but are not limited to, shortness of breath, pitting edema, an enlarged and tender liver, engorged neck veins, and pulmonary rales in various combinations.
- Symptoms are “reduced” when the magnitude (e.g. intensity) or frequency of symptoms is reduced. It is not intended that the present invention be limited only to cases where the symptoms are eliminated. The present invention specifically contemplates treatment such that symptoms are reduced (and the condition of the subject is thereby “improved”), albeit not completely eliminated.
- In a preferred embodiment, the subject is a human and the oral dosage of either the (+) or (−) enantiomer of flosequinan is in a single dose per day of up to approximately two hundred milligrams. In another embodiment said dosage is between approximately twenty-five to approximately seventy-five milligrams. In another embodiment, the (+) or the (−) enantiomer is administered in a single oral dose per day of between approximately one hundred and twenty-five and approximately two hundred milligrams. In another embodiment, the administration of said enantiomers of flosequinan comprises three daily doses, before meals, each dose of up to approximately two hundred milligrams per dose. In another embodiment, said daily doses comprise between approximately twenty-five to approximately seventy-five milligrams per dose. In another embodiment, said daily doses comprise between approximately one hundred and twenty-five and approximately two hundred milligrams per dose.
- In selected embodiments said enantiomers of flosequinan are introduced orally, cutaneously, by standard injection (e.g. intravenously), or intranasally.
- In one embodiment, the method comprises a) providing: i) a patient suffering from symptoms of cardiac disease who is not being administered nitrates or nitrites; and ii) an enantiomer of flosequinan; and b) introducing said enantiomer of flosequinan to said patient such that said symptoms of cardiac disease are reduced.
- In one embodiment, said substantially purified enantiomer of flosequinan is a (+) enantiomer. In another embodiment, said composition is substantially free of the (−) enantiomer of flosequinan.
- In one embodiment, the method comprises a) providing: i) a subject suffering from symptoms of cardiovascular disease; and ii) a purified enantiomer preparation of flosequinan, or a pharmaceutically acceptable salt thereof; and b) administering said preparation to the subject such that symptoms are reduced. In one embodiment, said cardiovascular disease is selected from the group consisting of hypertension, angina pectoris, myocardial infarction, and congestive heart failure. Said administering step is selected from the routes consisting of intranasal and respiratory inhalation.
- In another embodiment, the method comprises a) providing: i) a subject suffering from symptoms of cardiovascular disease who is not being treated with a drug that causes hypotensive effects, and ii) a purified enantiomer preparation of flosequinan, or a pharmaceutically acceptable salt thereof; and b) administering said preparation to the subject such that such symptoms are reduced.
- In another embodiment, the method comprises a) providing: i) a subject suffering from symptoms of cardiovascular disease who is not being treated with a nitrite or nitrate, and ii) a purified enantiomer preparation of flosequinan, or a pharmaceutically acceptable salt thereof; and b) introducing said preparation to the subject such that such symptoms are reduced. Said nitrate is selected from the group consisting of glyceryl trinitrate, isosorbide dinitrate, isosorbide-5′-mononitrate, and erythrityl tetranitrate.
- It is not intended that the present invention be limited by the method of introduction of a purified enantiomer preparation of flosequinan, or a pharmaceutically acceptable salt thereof. In one embodiment, the enantiomer of flosequinan is introduced orally. In a preferred embodiment, an adult human is provided an oral dosage as a single dose per day of 10 to 200 milligrams. In other embodiments, enantiomers of flosequinan are introduced cutaneously, by standard injection, intranasally, or through respiratory inhalation.
- The present invention is not limited by the degree of response by the subject. In one embodiment, relief of pain from angina pectoris is sufficient.
- It is not intended that the present invention be limited by the nature of the formulation. In one embodiment, the present invention contemplates a mixture of a purified enantiomer of flosequinan and a carrier, i.e. a mixture comprising lactose.
- In one embodiment, the enantiomers recited in the present invention are introduced into said subject by oral administration or cutaneous administration. In another embodiment, said subject is an adult human and said oral administration comprises up to approximately 200 milligrams of flosequinan.
- In a preferred embodiment, the enantiomers of flosequinan recited in the present invention are administered to a subject who has not been treated in the past with a drug that causes hypotensive effects. In a more preferred embodiment, the enantiomers of flosequinan recited in the present invention are administered to a subject who is not being treated with a nitrite or nitrate. In one embodiment said nitrate is selected from the group consisting of glyceryl trinitrate, isosorbide dinitrate, isosorbide-5-mononitrate and erythrityl tetranitrate.
- The present invention also contemplates a method, comprising: a) providing: i) a subject suffering from a symptom of a cardiovascular disease selected from the group of hypertension and congestive heart failure and; ii) a purified enantiomer preparation of flosequinan and; b) administering said preparation to said subject under conditions such that said symptom is reduced. In a preferred embodiment, said purified enantiomer of flosequinan is the (+) enantiomer. In another preferred embodiment, said purified enantiomer of flosequinan is the (−) enantiomer.
- In one embodiment, the enantiomer preparation introduced into said subject by oral or cutaneous administration. In one embodiment said subject is an adult human and said oral administration, of said enantiomer preparation, comprises up to approximately 200 milligrams of flosequinan.
- The present invention also contemplates a purified flosequinan enantiomer preparation comprising a carrier.
-
FIG. 1 depicts the chemical structure of a quinolinone (top) and 16 C-7 substituents (bottom). -
FIG. 2 depicts the respective HPLC column retention times and optical rotations of the enantiomers of flosequinan separated by the method provided in Example 2. -
- As used herein, the phrase “derivatives of quinolinone” refers to chemical compositions comprising quinolinone with a chemical group attached, including (but not limited to) halogenated quinolinones.
- As used herein, the phrases “methylsulphinyl derivatives of quinolinone” refers to chemical compositions comprising quinolinone with a methylsulphinyl group attached. Examples include flosequinan (7-fluoro-1-methyl-3-(methylsulphinyl)-4(1H)-quinolone; 7-fluoro-1-methyl-3-(methylsufinyl)-4(1H)-quinolinone): and sulfone metabolites of flosequinan:
and sulfone metabolites of flosequinan: - As used herein, “drugs that have hypotensive effects” are those drugs which, when administered, cause the subject's end-diastolic blood pressure to be reduced. Nitrates are commonly used drugs which have hypotensive effects.
- As used herein, “nitrates” are compounds that contain the —NO3— moiety. Nitrates typically used in the clinic are shown in Table 1.
- As used herein, “nitrites” are compounds that contain the —NO2— moiety. Nitrites typically used in the clinic are shown in Table 1.
- As used herein “standard injection” refers to the placement of a pharmaceutical composition into a subject (e.g., with a hypodermic needle). For example, such injection can be made subcutaneously, intravenously, intramuscularly, intracavemosally, etc.
- As used herein, “by oral administration” refers to the introduction of a pharmaceutical composition into a subject by way of the oral cavity (e.g., in aqueous liquid or solid form).
- As used herein, the term “subject” refers to both humans and animals.
- As used herein, “cutaneously” refers to the introduction of a pharmaceutical composition into a subject by application to the surface of the skin such that the composition is absorbed into the subject.
- As used herein, “intranasally” refers to the introduction of a pharmaceutical composition within the nasal cavity.
- As used herein, “respiratory inhalation” refers to the introduction of a pharmaceutical composition within the respiratory tract.
- As used herein “single dosage” refers to a pharmaceutical composition of a formulation that is capable of achieving its intended effect in a single administration or application.
- As used herein, “symptoms of cardiovascular disease” refers to any clinical manifestation of a disease state associated with the heart and vasculature. For example, said clinical manifestation include: angina pectoris, myocardial infarction, congestive heart failure, cardiomyopathy, hypertension, arterial stenosis, and venous stenosis. The present invention specifically contemplates treatment such that symptoms are reduced (and the condition of the subject is thereby “improved”), albeit not completely eliminated.
- As used herein, “congestive heart failure” is a specific cardiovascular disease which is characterized, but not limited to, the following symptoms: shortness of breath, pitting edema, an enlarged and tender liver, engorged neck veins, and pulmonary rales in various combinations.
- The terms “lower alkyl”, “lower alkoxy”, “lower alkanoyl”, and “lower alkythio” denote such groups containing 1-8 carbon atoms, especially 2-4 carbon atoms for lower alkanoyl and 1-4 carbon atoms for the other groups. Examples of such groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-heptyl, n-octyl, methoxy, ethoxy, propoxy, n-butoxy, isobutoxy, acetyl, propionyl, butyryl, methylthio, ethylthio, propylthio and n-butylthio.
- As used hereinafter, the term “active compound” denotes a pyridinone compound of general formula I (as illustrated and described below in the section entitled “Other Compounds Useful In The Treatment of Cardiovascular Disease”), or a quinolinone or quinolinone derivative as illustrated and described above.
- As used herein, the term “diastereoisomers” refers to stereoisomers that are not mirror images of each other.
- As used herein, the term “enantiomer” refers to stereoisomers of molecules that are non-superimposable mirror images of each other. Enantiomers have identical physical properties, such as melting points and boiling points, and also have identical spectroscopic properties. Enantiomers differ from each other with respect to their interaction with plane-polarized light and with respect to their biological activity.
- As used herein, the term “stereoisomer” refers to compounds that have their atoms connected in the same order but differ in the arrangement of their atoms in space. (e.g. cis-2-butane and trans-2-butane).
- As used herein, the term “racemic mixture” refers to a mixture of the two enantiomers of one compound. An ideal racemic mixture is one wherein there is a 50:50 mixture of both enantiomers of a compound such that the optical rotation of the (+) enantiomer cancels out the optical rotation of the (−) enantiomer.
- As used herein, the terms “purified enantiomer” and “purified enantiomer preparation” are meant to indicate a preparation (e.g. derived from a racemic mixture or synthesized de novo) wherein one enantiomer has been enriched over the other, and more preferably, wherein the other enantiomer represents less than 10%, and more preferably less than 5%, and still more preferably, less than 2% of the preparation.
TABLE 1 NONPROPRIETARY NAMES AND TRADE CHEMICAL PREPARATIONS, USUAL DOSES, AND NAMES STRUCTURE ROUTES OF ADMINISTRATION* Amyl nitrite (isoamyl nitrite) Inh: 0.18 or 0.3 ml, inhalation Nitroglycerin (glyceryl trinitrate; NITRO-BID, NITROSTAT, NITROL, NITRO-DUR, others) T: S: C: B: O: D: IV: 0.15 to 0.6 mg as needed 0.4 mg per spray as needed 2.5 to 9 mg two to four times daily 1 mg every 3 to 5 h 1.25 to 5 cm (½ to 2 in.), topically to skin every #4 to 8 h 1 disc(2.5 to 15 mg) every 24h 5 μg/min; increments of 5 μg/minIsosorbide dinitrate (ISORDIL, SORBITRATE, DILATRATE, others) T: T(C): T(O): C: 2.5 to 10 mg every 2 to 3 h 5 to 10 mg every 2 to 3h 10 to 40 mg every 6 h 40 to 80 mg every 8 to 12 hIsosorbide-5-mononitrate (IMDUR, ISMO, others) T: C: 10 to 40 mg twice daily 60 mg daily Erythrityl tetranitrate (CARDILATE) T: T(O): 5 to 10 mg as needed 10 mg three times daily
*buccal (transmucosal) tablet; C, sustained-release capsule or tablet; D, transdermal disc; Inh, inhalant; IV, intravenous injection; O, ointment S, lingual spray; T, tablet for sublingual use; T(C), chewable tablet; T(O), oral tablet or capsule.
- As used herein, the phrase “pharmaceutically acceptable salts” or “a pharmaceutically acceptable salt thereof” refer to salts prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids and bases and organic acids and bases. Since the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids. Suitable pharmaceutically acceptable acid addition salts for the compound of the present invention include acetic, benzenesulfonic (besylate), benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic, and the like. Preferred acid addition salts are the chloride and sulfate salts.
- The present invention relates to methods for the treatment of cardiovascular disease. In one embodiment, the present invention contemplates compositions and methods for the treatment of CHF and hypertension. These compositions comprise quinolinones, including derivatives and enantiomers thereof. A variety of quinolinone derivatives are shown in
FIG. 1 . Methods for producing antibiotic derivatives of a particular quinolone carboxylic acid skeleton are provided in U.S. Pat. No. 4,623,650 to Gilligan et al., hereby incorporated by reference. - While the present invention is not limited by the nature of the derivatives, in one embodiment, the present invention encompasses the use of a variety of quinolinone derivatives (e.g., 5-bromoquinoline, 5-nitroisoquinoline, 8-nitroisoquinoline and 1-methylisoquinoline). One skilled in the art can readily produce such derivatives as set forth in McMurry, Organic Chemistry, 2nd Ed., Brooks/Cole Publishing, Belmont, CA (1988), pages 1044-1045 and 1076.
- In another embodiment, the present invention contemplates the use of methylthio and methylsulplinyl derivatives of quinolinone. In a preferred embodiment, the methylsulphinyl derivative is flosequinan (whether as a racemic mixture or as a purified enantiomer).
- In another embodiment, the present invention contemplates compositions and methods for the treatment of CHF and hypertension in subjects who are not concurrently being treated with nitrites or nitrates. In a preferred embodiment, the present invention contemplates the administration of the enantiomers of flosequinan as a methods of treating CHF and hypertension. In another embodiment, the optically active derivatives and metabolites of flosequinan are also contemplated.
- In one embodiment, a purified enantiomer preparation of flosequinan is administered. It is contemplated that an enantiomer of flosequinan be administered cutaneously, by standard injection, intranasally, or through respiratory inhalation. It is not intended that the methods of the present invention be limited to the mode of administration of an enantiomer of flosequinan.
- A. Evaluation of Compounds for Efficacy as Anti-Hypertensives
- The antihypertensive effects exerted by the enantiomers of flosequinan is readily demonstrated by means of tests on standard laboratory animals. It is not intended that the present invention be limited by the species of animal used as a test platform. Suitable animal models include, but are not limited to, species including rodents, non-human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, and aves.
- In one embodiment, female rats (weight range 180-240 g) of the Aoki-Okamoto strain of spontaneously hypertensive can be used. The rats are divided into groups of four and will be fasted overnight before administration of either the (+) or (−) enantiomer of flosequinan. Blood pressure will be determined in the following way. The rats are placed in a restraining cage, maintained at 38° C., with their tails protruding through holes in the cage. After 30 minutes in the cage, blood pressure will be measured using an inflatable cuff placed round the base of the tail and arterial pulsations will be monitored with a pneumatic pulse transducer. In other animal models, however, a limb or a phalanx as a site to monitor blood pressure. A pressure, greater than the expected blood pressure, will be applied to the cuff and this pressure will be slowly reduced. The pressure in the cuff at which arterial pulsations reappears will be recorded as the blood pressure. The rats will be removed from the cage and each group will be orally administered a given dose of either the (+) or (−) enantiomer of flosequinan. In addition to the pre-dose reading, blood pressure will be measured at 1.5 and 5.0 hours after dosing. In one embodiment, a effective dosage will be defined as follows.
- Either the (+) or (−) enantiomer of flosequinan will be tested initially at a given dose level (for example 90 mg/kg). If the compound is considered sufficiently active (giving a reduction of blood pressure equal to or greater than of approximately 15% after correction) it will be retested at a lower dose level, for example 30 mg/kg. By testing at successively lower dose levels, a threshold antihypertensive dose (dose giving a reduction of blood pressure of between 5 and 15% after correction) will be determined. Compounds which are inactive at a particular dose level and which produce a reduction of blood pressure equal to or greater than 15% after correction at the next highest dose level will be designated as having a threshold antihypertensive dose within the range covered by the two dose levels.
- The above described protocol is suited it a variety of hypertensive and normotensive animal models. In a preferred embodiment, a normotensive marmoset monkey will be used.
- B. Evaluation of Compounds for Efficacy in the Treatment of CHF
- 1. Surgical Preparation
- Mature M. fascicularis primates will be premedicated with ketamine hydrochloride (15 mg/kg im) and glycopyrrolate (0.01 mg/kg im). Following intubation, anesthesia will be maintained with 0.5% to 1% isoflurane. A left thoracotomy, including removal of the fourth or fifth rib, will be performed under sterile conditions and the pericardium will be opened and reflected to expose the heart. Silastic catheters attached to subcutaneous vascular access ports (VAPs; Access Technology) will be inserted into the descending thoracic aorta and into the right atrium via the atrial appendage. To measure LV pressure, a solid-state micromanometer (Konigsberg Instruments) will be introduced via a stab wound in the ventricular apex and secured with a purse-string suture. A unipolar pacing lead will be sutured to the posterior wall of the LV and connected to a programmable pacemaker (Medtronic, Model Minix 8340) that will be situated subcutaneously over the left chest wall. Internal electrocardiogram (ECG) leads will be sutured to the chest wall. All catheters and wires will be tunneled subcutaneously to the dorsal midline below the scapula. Transdermal titanium skin buttons (Konigsberg Instruments) attached to the wires from the LV pressure transducer and ECG leads will be secured along the midline, while the catheter VAPs will be situated in subcutaneous pockets. The chest will be closed in layers and negative intrapleural pressure restored via a temporary chest tube. Antibiotics (Cefazolin, 30 mg/kg) will be administered subcutaneously prior to surgery and postoperatively for 10 days (30 mg/kg bid). Buprenorphine (0.01 mg/kg sq) will be administered for analgesia immediately after surgery and as needed the first postoperative week. All monkeys will be allowed to recover for a minimum of 2 weeks after surgery and were conditioned to sit in upright/reclining primate restraint chairs prior to commencement of experimental investigations.
- 2. Hemodynamic Measurements
- Arterial blood pressure will be measured by inserting into the aortic VAP a saline-filled needle-tipped catheter, the other end of which was connected to a Statham P23 XL pressure transducer. Intravenous agents will be delivered via a similar catheter extension set inserted into the right atrial VAP. Left ventricular pressure (LVP) will be measured via the Konigsberg micromanometer and will be cross-calibrated with the aortic pressure signal, and the transthoracic ECG will be measured using a Gould ECG/Biotach amplifier (Gould Instrument Systems). All physiological signals will be sampled at 500 Hz using a computerized digital data acquisition system (Po-Ne-Mah, Gould Instrument Systems), while being simultaneously recorded on digital audio tape (Model RD 111T, Teac) and displayed on an MT 95000 eight-channel thermal-array recorder (Astro-Med). Measurements of heart rate (HR), mean arterial blood pressure (MAP), left ventricular systolic and end-diastolic blood pressures (LVSP and LVEDP, respectively), and the peak positive rate of change in LVP (+dP/dtmax) will derived using algorithm-based analyses of the digitized waveforms.
- 3. Myocardial Function Measurements
- LV dimensions will be recorded with the primates under ketamine sedation using M-mode echocardiographic imaging (Hewlett Packard Sons 100CF) of the LV via a left transthoracic approach. Images will be recorded on VHS tape for subsequent calculation of LV fractional shortening and wall thickening percentage (WT) from the short axis and wall thickness dimensions. In addition, ejection fraction (EF) will be calculated by applying the Teicholz formula to the respective short axis dimensions measured at end-diastole and end-systole (EDV=[7/(2.4+LVDd)](LVDd3) and ESV=[7/(2.4+LVD5)](LVD5 3) for end diastolic and end systolic volumes, respectively). Utilizing simultaneous ECG recordings on the videotape, end-diastolic dimensions will be defined as occurring at the peak of the R-wave, while end-systole will be associated with the peak of the T-wave. Systolic WT will be then calculated as the difference between end-systolic and end-diastolic dimensions and is expressed as percent change from end-diastolic thickness [(EST−EDT)/EDT]×100.
- It is not intended, however, that the present invention be limited by the species of the animal model used to evaluate the efficacy of a given compound as potential CHF therapeutic. The above described protocol is suited it a variety of hypertensive and normotensive animal models. In a preferred embodiment, a normotensive marmoset monkey will be used.
- The compositions utilized in the methods of the present invention comprise purified enantiomers of flosequinan, including derivatives thereof. Although the present invention is not limited by a specific means of producing enantiomers of flosequinan, methods of producing a racemic mixture of flosequinan (and methylsuphinyl/methylthio derivatives of quinolinone) are set forth in U.S. Pat. Nos. 5,079,264 and 5,011,931 to MacLean et al., hereby incorporated by reference. Moreover, a means of resolving the enantiomers of flosequinan is set forth in Morita et al., “Synthesis and Absolute Configuration of the Enantiomers of 7-Fluoro-1-methyl-3-(methylsulfinyl)-4(1H)-quinolinone (Flosequinan),” Chem. Pharm. Bull., 42(10): 2157-2160 (1994), hereby incorporated by reference.
- C. Resolution of the (+) and (−) Enantiomers of Flosequinan
- In a preferred embodiment, the present invention contemplates the administration of a purified enantiomer of flosequinan. Many organic compounds, including flosequinan, exist in optically active forms (i.e., they have the ability to rotate the plane of plane-polarized light). In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and l or (+) and (−) are employed to designate the sign of rotation of plane-polarized light by the compound, with (−) or l meaning that the compound is levorotatory (rotates to the left). A compound prefixed with (+) or d is dextrorotatory (rotates to the right).
- The present invention is not limited by any specific means of resolving the (+) and (−) enantiomers of flosequinan to obtain a substantially purified enantiomer of flosequinan. In one embodiment, the enantiomers were resolved according to the methods in Example 2.
- It is not intended that the present invention be limited to any specific mechanism. However, the enantiomers of flosequinan can function as a vasodilator. This vasodilation decreases the total peripheral resistance offered by the vasculature, thereby, decreasing blood pressure. Flosequinan has also been reported to be a selective inhibitor of phosphodiesterase III (PDE3). (See Gristwood et al., Br. J. Pharmacol., 105: 985 (1992); Frodsham et al., Eur. J. Pharmacol. 211: 383 (1992)). Inhibitors of PDE3 cause vasodilation leading to a concomitant reduction in arterial blood pressure. See Shiraishi et al., Br. J. Pharmacol., 123: 869-878 (1998).
- It is not intended that the present invention be limited to any particular mechanism to reduce symptoms of cardiovascular disease. In one embodiment, the (+) and (−) enantiomers of flosequinan were subjected to biochemical assays to determine their respective percent inhibition of PDE3. In one embodiment, it was shown that the (+) enantiomer of flosequinan has an eight-fold increase in PDE3 inhibition as compared to that of the (−) enantiomer of flosequinan at the same molar concentration. Moreover, in the same embodiment, the (+) enantiomer of flosequinan exhibited greater inhibition of PDE3 than a racemic mixture of flosequinan at the same molar concentration. Further data concerning this is provided in Example 3.
- Moreover, it is not intended that the present invention be limited to any particular mechanism to reduce the side effects associated with various pharmacological treatments for cardiovascular disease. In one embodiment, a 100 μM mixture of the (+) and (−) enantiomers of flosequinan were subjected to biochemical assays to determine their respective percent inhibition of PDE6 as compared to that of sildenafil citrate at a concentration of 1 μM. In one embodiment, it was shown that the mixture of the (+) and (−) enantiomers of flosequinan exhibited approximately half as much inhibition of PDE6 as compared to that of a 100-fold lower molar concentration of sildenafil citrate. Further data concerning this is provided in Example 1.
- Diagnosis of Cardiovascular Disease
- Determination whether an adult human is suffering from cardiovascular disease is readily made by a person skilled in the art using a number of readily available diagnostic procedures. Thus, an adult human suffering from cardiovascular disease can first be given a physical examination with particular attention to possible blood pressure or heart rhythm pathology, whereby many anatomical electophysiological cardiovascular abnormalities can be detected.
- Tests to determine hypertension may be performed by doppler investigation of the venous blood return system sufficiency. Blood pressures can be determined by a number of standard techniques.
- Tests to determine myocardial infarction include detecting aberrations in blood enzymes. Following a myocardial infarction the damaged heart cells release of lactate dehydrogenase (LDH) subtypes result in circulating ratios that are not normally observed in a healthy person.
- Test to determine angina pectoris include testing procedures as with myocardial infarction, only with the appearance of normal LDH subtype ratios.
- Test to determine congestive heart failure include comparisons of blood pressures, cardiac output and stroke volume measurement. Congestive heart failure is a debilitating progressive condition that is fatal if immediate action is not taken.
- Treatment of Cardiovascular Disease
- It is not intended that the present invention be limited by the particular nature of a preparation. In one embodiment, the (+) enantiomer of flosequinan is provided together with physiologically tolerable liquid, gel or solid carriers, diluents, adjutants and excipients. In addition, enantiomers of flosequinan may be used together with other chemotherapeutic agents. On the other hand, formulations may also contain such normally employed additives as binders, fillers, carriers, preservatives, stabilizing agents, emulsifiers, buffers and excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions typically contain 1%-95% of active ingredient, preferably 2%-70%.
- The present invention is not limited by the method of introduction of the compound to the body. Among other methods, the present invention contemplates administering cutaneously, orally, or by standard injection (e.g. intravenous).
- The present invention also contemplates administering the enantiomers of flosequinan to the subject intranasally or through respiratory inhalation. Formulations suitable for intranasal administration include ointments, creams, lotions, pastes, gels, sprays, aerosols, oils and other pharmaceutical carriers which accomplish direct contact between an enantiomer of flosequinan or a pharmaceutical composition comprising an enantiomer of flosequinan and the nasal cavity. Examples of pharmaceutical compositions administered intranasally are described in U.S. Pat. Nos. 5,393,773 and 5,554,639 to Craig et al.; and 5,801,161 to Merkus, all hereby incorporated by reference. Formulations suitable for respiratory inhalation include ointments, creams, lotions, pastes, gels, sprays, aerosols, oils and other pharmaceutical carriers which accomplish direct contact between an enantiomer of flosequinan or a pharmaceutical composition comprising an enantiomer of flosequinan and the respiratory tract. Examples of pharmaceutical compositions administered through respiratory inhalation are described in U.S. Pat. No. 4,552,891 to Hu et al.; U.S. Pat. No. 5,869,479 to Kreutner et al., and U.S. Pat. No. 5,864,037 to Chasis et al., all hereby incorporated by reference.
- In some embodiments, intranasal administration and respiratory inhalation are the preferred modes of administration due to the ease of administration and faster onset of therapeutic activity. It is contemplated that intranasal administration and respiratory inhalation are advantageous as they may allow a smaller effective dosage to be administered than would be possible with the oral route of administration. A preferred mode of administration comprises administration to the lung. Intrapulmonary delivery of pharmacologic agents to subjects can be accomplished via aerosolization. Alternatively, the agent may be administered to the lung through a bronchoscope. Of course, the therapeutic agents may be investigated for their efficacy via other routes of administration, including parenteral administration.
- Oral administration of an enantiomer of flosequinan is an effective mode of administration, with a mean absolute bioavailability of 72% following a single dose of fifty milligrams. Peak plasma concentrations of an enantiomer of flosequinan are observed 1-2 hours following oral administration, while peak metabolite plasma levels are observed about seven hours following oral dosage. While the present invention is not limited to a specific dosage level, for adult humans, in one preferred embodiment the dosage is a single dosage per day of 10 milligrams, while in another preferred embodiment the dosage is a single dosage per day of 25 milligrams, while in another preferred embodiment the dosage is a single dosage per day of 50 milligrams, while in yet another preferred embodiment the dosage is a single dosage per day of 75 milligrams. In another preferred embodiment, the dosage is a single dosage per day of approximately 125 milligrams and in another preferred embodiment, the dosage is a single dosage per day of approximately 150 milligrams. In another preferred embodiment, the dosage is a single dosage per day of approximately 200 milligrams. Multiple dosage is also contemplated.
- Flosequinan and its enantiomers are water soluble and soluble in many organic solvents. Thus, while the present invention is not limited by the form of oral administration, aqueous and organic solution of an enantiomer of flosequinan for oral administration is contemplated. Likewise, an enantiomer of flosequinan can be associated with a solid pharmaceutical carrier for solid oral administration (i.e., in pill form). One skilled in the art is able to readily prepare such solid formulations, and in one embodiment, the inactive ingredients include croscarmellose sodium, hydroxypropyl methylcellulose, lactose, magnesium stearate, methocel E5, microcrystalline cellulose, povidine, propylene glycol and titanium dioxide.
- The enantiomers of flosequinan may also be administered cutaneously in a carrier adapted for topical administration. Such carriers include creams, ointments, lotions, pastes, jellies, sprays, aerosols, bath oils, or other pharmaceutical carriers which accomplish direct contact between an enantiomer of flosequinan and the pore of the skin. In general pharmaceutical preparations may comprise from about 0.001% to about 10%, and preferably from about 0.01 to 5% by w/w of the active compound (e.g., an enantiomer of flosequinan) in a suitable carrier. In some cases it may be necessary to dissolve the active compound in an appropriate solvent such as ethanol or DMSO (dimethylsulfoxide), and the like, to facilitate incorporation into a pharmaceutical preparation.
- While the present invention is not limited by a specific method of introducing an enantiomer of flosequinan by injection, injection of an enantimer of flosequinan (or a formulation comprising an enantiomer of flosequinan) can be carried out by any conventional injection means (e.g., employing an hypodermic syringe and needle or a similar device such as the NovolinPen sold by Squibb-Novo, Inc., Princeton, N.J., USA). This injection may be by the subject injecting him or herself or by another person injecting the subject.
- Flosequinan and its enantiomers can be introduced by injection in a physiologically acceptable composition. Such compositions are aqueous solutions that are physiologically acceptable for administration by injection. The physiologically acceptable carrier is selected such that it is not painful or irritating upon injection. The physiologically acceptable compositions will preferably be sterile at the time of administration by injection.
- Among the physiologically acceptable compositions for use in the methods is physiological saline or phosphate buffered saline, in which the enantiomers of flosequinan are dissolved or suspended, such that the resulting composition is suitable for injection. Such a physiologically acceptable composition can also include a non-irritant preservative, such as, e.g., benzalkonium chloride at 0.05% (w/v) to 0./2% (w/v). As the skilled artisan will understand, there are numerous non-toxic salts of VIP, PHM and α-adrenergic blockers that can be employed in a physiologically acceptable composition for use in the methods herein, including, among others, the chloride, bromide, acetate, sulfate, and mesylate salts.
- While the present invention is not limited to the method of injecting the enantiomers of flosequinan, in the preferred embodiment, it is injected with a standard syringe. One skilled in the art would be capable of injecting the enantiomers of flosequinan with a carrier as described above.
- In view of the above, the present invention provides methods for the treatment human cardiovascular disease with the enantiomers of flosequinan (or a formulation comprising the enantiomers of flosequinan).
- Other Compounds Useful in the Treatment of Cardiovascular Disease
- The invention is further directed to pyridinone compounds with therapeutic activity, and to compositions containing such compounds, wherein the compounds have the general formula I:
R1 is hydrogen, lower alkyl optionally substituted by hydroxy or C1-4 alkoxycarbonyl, allyl, propynyl or phenyl-lower alkyl in which the phenyl ring is optionally substituted by 1 or 2 C1-4 alkoxy groups; R2 is hydrogen or lower alkyl; R3 is (X)m—S(O)nR4, COR5, SR6, or S(OH) (O)NR7, wherein m is 0 or 1, n is 0, 1, or 2, X is oxygen or lower alkylene, R4 is C1-4 alkyl, R5 is hydroxyl, lower alkyl carbonyl, amino, or lower alkyl amino, and R6 and R7 are lower alkyl; and ring A represents an optionally substituted phenyl ring of the formula:
wherein R8, R9 and R10, which may be the same or different, are hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, halo, tri-fluoromethyl, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, halogenated lower alkyl, halogenated lower alkoxy, cyano, phenyl, or phenyl substituted by 1 to 3 groups independently selected from lower alkyl, lower alkoxy and trifluoromethyl; or ring A represents an optionally substituted thiophene ring of the formula:
wherein R11 is hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, halo, trifluoromethyl, lower alkylthio, phenyl, or phenyl substituted by halogen, or a pharmaceutically acceptable salt thereof. - The compounds of the general formula I have been found to have antihypertensive activity and cardiac activity in warm-blooded animals. The compounds, methods of making the compounds, antihypertensive and cardiac therapeutic compositions of the compounds, and methods for treating hypertension and heart failure using the compounds are described in U.S. Pat. No. 4,302,460, U.S. Pat. No. 4,522,884, U.S. Pat. No. 4,855,291, U.S. Pat. No. 4,877,793, U.S. Pat. No. 4,710,506, U.S. Pat. No. 4,772,614 and U.S. Pat. No. 4,997,840, the disclosures of which patents are expressly incorporated herein, in their entirety, by reference.
- In a preferred embodiment, the invention provides pharmaceutical compositions comprising compounds of the general formula I, and methods of using the compositions to treat subjects with symptoms of cardiovascular disease, such that said symptoms are reduced. As described above for the enantiomers of flosequinan, the invention is not limited by the particular nature of the pharmaceutical composition, or by the method of introduction of the active or therapeutic compound to the body. All of the treatment methods and compositions contemplated above are also contemplated here for compounds of formula I. The active ingredient in the compositions is preferably administered in unit dosage form. In one embodiment, tablets and capsules may conveniently contain a unit dosage of the active compound of 1-500 mg/kg, more preferably 5-100 mg/kg and still more preferably 5-50 mg/kg.
- The compounds of formula I may contain one or more asymmetric centers and, therefore, can exist as enantiomers or diastereoisomers. Furthermore, certain compounds of formula I containing alkenyl groups may exist as cis-isomers or transisomers. In each case, the invention includes both mixtures and separate individual isomers. The compounds of formula I may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers.
-
-
- (a) R10 is hydrogen and R9 is 6-lower alkoxy, 8-lower alkoxy, 5-halo or 6-halo;
- (b) R9 is hydrogen and R10 is halo; lower alkyl, lower alkoxy, trifluoromethyl or lower alkyl-thio;
- (c) R10 is halo, lower alkoxy or lower alkyl and R9 is 6-lower alkyl, 6-lower alkoxy or 6-halo of a different value from R10; or
- (d) R9 and R10 are hydrogen.
- Preferred embodiments include compounds of formula IIA wherein R1 and R2 are methyl, R9 is hydrogen and R10 is halo, lower alkyl or trifluoromethyl. More preferably, R10 is halo or C1-C4 alkyl. In yet another preferred embodiment, R9 is 6-lower alkoxy and R10 is halo or lower alkoxy. In a further preferred embodiment, R9 is 6-halo and R10 is lower alkoxy. In another preferred embodiment, R10 is C1-C4 alkyl.
- Thus, preferred embodiments include compounds of formula IIB, IIC, IID, IIE, IIF, IIIA and IIIB as follows:
Preferred compounds of formula IIB are those in which m is 1, n is 2, and X is oxygen. Preferred compounds of formula IIC include those in which m is 0, n is 1 or 2, and R4 is methyl. Preferred compounds of formula IID include those in which R5 is amino or lower alkyl amino. Preferred compounds of formula IIE include those in which R6 is methyl. Preferred compounds of formula IIF include those in which R7 is methyl. Preferred compounds of formula IIIA include those in which n is 1 and R4 is methyl. Preferred compounds of formula IIIB include those in which R5 is amino or lower alkyl amino. - Specific preferred compounds of these formulae include: 1-methyl-3-methylsulphinyl-4-quinolone, 7-fluoro-1-methyl-4-oxo-1,4-dihydroquinolone-3-carboxamide, 4-methyl-7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide, 4-methyl-6-methylsulphinyl-7(4H)-thieno[3,2-b]pyridinone, 7-chloro-1-methyl-3-methylsulphamoyl-4-quinolone, 1-methyl-4-oxo-1,4-dihydroquinol-3-yl methanesulphonate, 7-chloro-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide, 7-fluoro-1-methyl-3-methylsulphonyl-4-quinolone, or 7-fluoro-1-methyl-3-methylthio-4-quinolone, or pharmaceutically acceptable salts thereof.
- Experimental
- The following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.
- In the experimental disclosure which follows, the following abbreviations apply: eq (equivalents); M (Molar); μM (micromolar); N (Normal); mol (moles); mmol (millimoles); μmol (micromoles); nmol (nanomoles); g (grams); mg (milligrams); μg (micrograms); L (liters); ml (milliliters); μl (microliters); cm (centimeters); mm (millimeters); μm (micrometers); nm (nanometers); ° C. (degrees Centigrade).
- In this example, a biochemical assay was performed to test the percentage of phosphodiesterase 6 (PDE6) inhibition of various molar concentrations of sildenafil citrate (Viagra) as compared to that of a 100 μM concentration of a racemic mixture of flosequinan as follows.
- PDE6 partially purified from bovine retinal rod and activated by trypsin was used. In four separate reactions, Viagra at molar concentrations of 0.3 μM, 1.0 μM, and 3.0 μM, and a 100 μM racemic mixture of flosequinan were incubated with 0.2 μg/ml active PDE6 and 100 μM cGMP containing 0.1 μM [3H]cGMP in Tris buffer pH 7.5 for 20 minutes at 30° C. Each reaction was terminated by raising the temperature to 100° C. for 2 minutes. The resulting GMP was converted to guanosine by addition of 10 mg/ml snake venom nucleotidase and further incubated at 30° C. for 10 minutes. Unhydrolyzed cGMP was bound to AGI-X2 resin, and [3H]guanosine remaining in the aqueous phase was quantitated by scintillation counting.
- The results of the assays, as noted in the table below, indicate that although Viagra inhibits PDE6 around 50% at concentrations as low as 0.3 μM, such levels of inhibition of PDE6 require greater than 100 μM amounts of flosequinan (i.e. more than 300 times more compound on a molar basis). These empirical results could not be predicted.
Compound Concentration % Inhibition of PDE6 Viagra 3.0 μM 87 Viagra 1.0 μM 62 Viagra 0.3 μM 57 Flosequinan 100 μM 36 - In this example, the enantiomers of flosequinan were resolved by high-performance liquid chromatography (HPLC) as follows. A 5.0 g sample of a racemic mixture of flosequinan was resolved over a 10 cm ID×50 cm L CHIRALCEL OD HPLC column (Chiral Technologies, Exton, PA) at 25° C. and with a flow rate of 1.0 ml/minute such that the column pressure was 37 bar. The mobile phase employed was 100% methanol and the detection of the mixture was performed at 270 nm. The (−) enantiomer had a retention time of 3.13 minutes, while the (+) enantiomer had a retention time of 4.40 minutes. A total of 2.1 g of the (−) enantiomer having an optical purity greater than 99% was produced. A total of 2.3 g of the (+) enantiomer having an optical purity greater than 99% was produced. (See,
FIG. 2 ). - In this example, a racemic mixture of flosequinan and the (+) and (−) enantiomers of flosequinan were subjected to biochemical enzyme assays to determine their respective percent inhibition of a variety of phosphodiesterases (PDEI-PDE6). The reaction conditions for each PDE assay were as follows.
- PDE1: PDE1 partially purified from bovine heart was used. A racemic mixture of flosequinan, and each enantiomer of flosequinan, all at a molar concentration of 100 μM, were independently incubated with 13 μg PDE1 enzyme, 1.0 μM [3H]cAMP and CaCl2/calmodulin in Tris buffer pH 7.5 for 20 minutes at 30° C. The reaction was terminated by boiling for 2 minutes, and the resulting AMP was converted to adenosine by addition of 10 mg/ml snake venom nucleotidase and further incubation at 30° C. for 10 minutes. Unhydrolyzed cAMP was bound to AGI-X2 resin, and the remaining [3H]adenosine in the aqueous phase was quantitated by scintillation counting.
- PDE2: PDE2 partially purified from human platelets was used. A racemic mixture of flosequinan, and each enantiomer of flosequinan, all at a molar concentration of 100 μM, were independently incubated with 23 μg PDE2 enzyme, 25 μM cAMP containing 0.05 μM [3H]cAMP in Tris buffer pH 7.5 for 20 minutes at 30° C. The reaction was terminated by boiling for 2 minutes, and the resulting AMP was converted to adenosine by addition of 10 mg/ml snake venom nucleotidase and further incubation at 30° C. for 10 minutes. Unhydrolyzed cAMP was bound to AGI-X2 resin, and the remaining [3H]adenosine in the aqueous phase was quantitated by scintillation counting.
- PDE3: PDE3 partially purified from human platelets was used. A racemic mixture of flosequinan, and each enantiomer of flosequinan, all at a molar concentration of 100 μM, were independently incubated with 13 μg PDE3 enzyme and 1 μM cAMP containing 0.01 μM [3H] cAMP in Tris buffer pH 7.5 for 20 minutes at 30° C. The reaction was terminated by boiling for 2 minutes, and the resulting AMP was converted to adenosine by addition of 10 mg/ml snake venom nucleotidase and further incubation at 30° C. for 10 minutes. Unhydrolyzed cAMP was bound to AGI-X2 resin, and the remaining [3H]adenosine in the aqueous phase was quantitated by scintillation counting.
- PDE4: PDE4 partially purified from human U-937 pronocytic cells was used. A racemic mixture of flosequinan, and each enantiomer of flosequinan, all at a molar concentration of 100 μM, were independently incubated with 20 μg PDE4 enzyme and 1 μM cAMP containing 0.01 μM [3H]cAMP in Tris buffer pH 7.5 for 20 minutes at 30° C. The reaction was terminated by boiling for 2 minutes, and the resulting AMP was converted to adenosine by addition of 10 mg/ml snake venom nucleotidase and further incubation at 30° C. for 10 minutes. Unhydrolyzed cAMP was bound to AGI-X2 resin, and the remaining [3H]adenosine in the aqueous phase was quantitated by scintillation counting.
- PDE5: PDE5 partially purified from human platelets was used. A racemic mixture of flosequinan, and each enantiomer of flosequinan, all at a molar concentration of 100 μM, were independently incubated with 120 μg PDE5 enzyme and 1 μM cGMP containing 0.01 μM [3H]cGMP in Tris buffer pH 7.5 for 20 minutes at 30° C. The reaction was terminated by boiling for 2 minutes, and the resulting GMP was converted to guanosine by addition of 10 mg/ml snake venom nucleotidase and further incubation at 30° C. for 10 minutes. Unhydrolyzed cGMP was bound to AGI-X2 resin, and the remaining [3H]guanosine in the aqueous phase was quantitated by scintillation counting.
- PDE6: PDE6 partially purified from bovine retinal rod and activated by trypsin was used. A racemic mixture of flosequinan, and each enantiomer of flosequinan, all at a molar concentration of 100 μM, were independently incubated with 0.2 μg/ml active PDE6 and 100 μM cGMP containing 0.1 μM [3H]cGMP in Tris buffer pH 7.5 for 20 minutes at 30° C. Each reaction was terminated by boiling for 2 minutes. The resulting GMP was converted to guanosine by addition of 10 mg/mil snake venom nucleotidase, and further incubated at 30° C. for 10 minutes. Unhydrolyzed cGMP was bound to AGI-X2 resin, and [3H]guanosine remaining in the aqueous phase was quantitated by scintillation counting.
- The results of the above PDE assays are presented in the following table. The (+) enantiomer of flosequinan demonstrated more PDE1 and PDE3 inhibitory activity when compared with the (−) enantiomer of flosequinan. These empirical results could not be predicted.
% Inhibition w/ 100 μM racemic % Inhibition w/ % Inhibition w/ Target mixture of 100 μM (+)- 100 μM (−)- Phosphodiesterase flosequinan flosequinan flosequinan PDE1 31 28 11 PDE2 18 18 13 PDE3 26 32 5 PDE4 24 6 1 PDE5 11 17 10 PDE6 21 22 21 - This example describes how certain preferred compounds of general formula (I) can be prepared.
- a. 7-fluoro-1-methyl-4-oxo-1,4-dihydroquinolone-3-carboxamide can be prepared as described in Example 1 of U.S. Pat. No. 4,855,291.
- (i) A mixture of ethyl 7-fluoro-4-hydroxyquinoline-3-carboxylate (4.7 g), anhydrous potassium carbonate (3.0 g), dimethyl sulphate (2.52 g) and butanone (200 ml) can be boiled under reflux for 14 hours. The solvent can be evaporated and the residue can be triturated with dichloromethane (150 ml). The mixture can be filtered and the filtrate evaporated to a small volume. Diethyl ether can be added, causing a solid to precipitate. The solid can be collected, washed with ether, dried and recrystallised from industrial methylated spirit to give the compound ethyl 7-fluoro-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate, m.p. 164° C.-166° C.
- (ii) A mixture of 19.0 g of the above carboxylate ester, aqueous ammonia (specific gravity 0.88, 750 ml) and caproyl alcohol (2 drops) can be stirred on a steam bath for 1.5 hours, then cooled to room temperature. The solid product can be collected by filtration and recrystallised from industrial methylated spirit/water 3:2 to give the compound 7-fluoro-1-methyl-4-oxo-1,4-dihydroquinoline3-carboxamide, m.p. 317° C.-318° C.
- b. 4-methyl-7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide can be prepared as described in Example 1 of U.S. Pat. No. 4,877,793.
- (i) Dimethyl sulphate (3.9 ml) can be added to a stirred solution of ethyl 7-hydroxythieno[3,2-b]-pyridine-6-carboxylate (4.63 g) and potassium hydroxide (3.5 g) in water (50 ml) at 0° C.-5° C. More water (20 ml) can be added and the mixture can be stirred at ambient temperature for 24 hours. The solid product can be collected by filtration, washed with water and dried to give the compound ethyl 4-methyl-7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxylate, m.p. 122° C.-128° C.
- (ii) A mixture of 3.0 g of the product from (i) above and aqueous ammonia (specific gravity 0.880, 60 ml) can be stirred and heated on a steam bath. Effervescence will occur and ocean-1-ol (2 ml) and more aqueous ammonia (specific gravity 0.880, 20 ml) can be added and heating on the steam bath can be continued overnight. The mixture can then be cooled to ambient temperature and the solid product collected by filtration, dried and crystallized from industrial methylated spirit to give the compound
- 4-methyl-7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide, m.p. 255° C.-258° C.
- c. 4-methyl-6-methylsulphinyl-7(4H)-thieno[3,2-b]pyridinone can be prepared as described in Example 2 of U.S. Pat. No. 4,710,506.
A solution of 3-chloroperbenzoic acid (85%; 1.63 g) in dichloromethane (60 ml) can be added dropwise during 20 minutes to a stirred solution of 4-methyl-6-methylthiothieno[3,2-b]pyrid-7(4H)-one (2.0 g) in dichloromethane (60 ml) at 0° C.-5° C. After 4 hours, more 3-chloroperbenzoic acid (0.15 g) in dichloromethane (10 ml) can be added and the mixture stirred overnight at ambient temperature. More 3-chloroperbenzoic acid (0.15 g) in dichloromethane (10 ml) can be added and the mixture can again be stirred overnight at ambient temperature. The resulting solution can be extracted with saturated aqueous sodium bicarbonate solution (5×150 ml) and saturated aqueous sodium chloride solution (1×150 ml) and the organic phase can be discarded. The aqueous extracts are combined and extracted with dichiloromethane (5×100 ml). The organic extracts are combined, dried over arhydrous magnesium sulphate and evaporated to give a solid product. This product can be crystallized from industrial methylated spirit to give the compound 4-methyl-6-methylsulphinylthieno[3,2-b]pyrid-7(4H)-one, m.p. 174° C.-176° C. - d. 7-chloro-1-methyl-3-methylsulphamoyl-4-quinolone can be prepared as described in Example 4 of U.S. Pat. No. 4,772,614.
- (i) 7-Chloro-1-methyl-4-quinolone (6.9 g) and chlorosulphonic acid (14 ml) can be stirred and heated at 140° C. for 2 hours. The reaction mixture can be cooled to room temperature and carefully added dropwise to ice water (200 ml). The solid which forms can be collected, washed with water and dried in air to give the compound 7-chloro-1-methyl-4-oxo-1,4-dihydroquinoline-3-sulphonyl chloride, m.p. >300° C.
- (ii) 6.5 g of the above sulphonyl chloride and aqueous methylamine (30% w/v; 220 ml) can be stirred at room temperature for 3 hours. The resulting solid can be collected, washed with water and crystallized from dichloromethane/industrial methylated spirit 1:1. The product can be collected and partitioned between water (200 ml) and dichloromethane (200 ml). The organic layer can be separated, dried over anhydrous sodium sulphate and evaporated to dryness. The residue can be crystallized from industrial methylated spirit to give the compound 7-chloro-1,N-dimethyl-4-oxo-1,4-dihydroquinoline-3-sulphonamide, m.p. 220° C.-223° C.
- e. 7-chloro-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide can be prepared as described in Example 4 of U.S. Pat. No. 4,855,291.
- A mixture of ethyl 7-chloro-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (5.0 g) and aqueous ammonia (specific gravity 0.88, 100 ml) can be stirred and heated on a steam bath for 3.5 hours. More aqueous ammonia (100 ml) can be added and heating continued for a further 21 hours. The mixture can be cooled in ice. The solid product can be collected by filtration and dried to give the compound 7-chloro-1-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide, m.p. >240° C.
- From the above, it should be clear that the present invention provides methods of treatment of symptoms of cardiovascular disease with pharmaceutical agents. In particular, quinolinone enantiomers are administered therapeutically to subjects having such symptoms.
Claims (19)
1. A method, comprising:
a) providing:
i) a subject suffering from a symptoms of cardiovascular disease and;
ii) a purified enantiomer preparation of flosequinan and;
b) administering said preparation to said subject under conditions such that said symptom is reduced.
2. The method of claim 1 , wherein said purified enantiomer of flosequinan is the (+) enantiomer.
3. The method of claim 1 , wherein said purified enantiomer of flosequinan is the (−) enantiomer.
4. The method of claim 1 , wherein said enantiomer of flosequinan is introduced into said subject by oral administration.
5. The method of claim 4 , wherein said subject is an adult human and said oral administration comprises up to approximately 200 milligrams of flosequinan.
6. The method of claim 1 , wherein said enantiomer of flosequinan is introduced into said subject cutaneously.
7. The method of claim 1 , wherein said subject has not been treated in the past with a drug that causes hypotensive effects.
8. The method of claim 1 , wherein said subject is not being treated with a nitrite or nitrate.
9. The method of claim 8 , wherein said nitrate is selected from the group consisting of glyceryl trinitrate, isosorbide dinitrate, isosorbide-5-mononitrate and erythrityl tetranitrate.
10. A method, comprising:
a) providing:
i) a subject suffering from a symptom of a cardiovascular disease selected from the group of hypertension and congestive heart failure and;
ii) a purified enantiomer preparation of flosequinan and;
b) administering said preparation to said subject under conditions such that said symptom is reduced.
11. The method of claim 10 , wherein said purified enantiomer of flosequinan is the (+) enantiomer.
12. The method of claim 10 , wherein said purified enantiomer of flosequinan is the (−) enantiomer.
13. The method of claim 10 , wherein said enantiomer of flosequinan is introduced into said subject by oral administration.
14. The method of claim 13 , wherein said subject is an adult human and said oral administration comprises up to approximately 200 milligrams of flosequinan.
15. The method of claim 10 , wherein said enantiomer of flosequinan is introduced into said subject cutaneously.
16. The method of claim 10 , wherein said subject has not been treated in the past with a drug that causes hypotensive effects.
17. The method of claim 10 , wherein said subject is not being treated with a nitrite or nitrate.
18. The method of claim 17 , wherein said nitrate is selected from the group consisting of glyceryl trinitrate, isosorbide dinitrate, isosorbide-5-mononitrate and erythrityl tetranitrate.
19. A purified flosequinan enantiomer preparation comprising a carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/435,999 US20050009866A1 (en) | 2001-01-26 | 2003-05-12 | Treatment of cardiovascular disease with quinolinone enantiomers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/771,104 US6562838B2 (en) | 2001-01-26 | 2001-01-26 | Treatment of cardiovascular disease with quinolinone enantiomers |
US10/435,999 US20050009866A1 (en) | 2001-01-26 | 2003-05-12 | Treatment of cardiovascular disease with quinolinone enantiomers |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/771,104 Continuation US6562838B2 (en) | 2001-01-26 | 2001-01-26 | Treatment of cardiovascular disease with quinolinone enantiomers |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050009866A1 true US20050009866A1 (en) | 2005-01-13 |
Family
ID=25090735
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/771,104 Expired - Fee Related US6562838B2 (en) | 2001-01-26 | 2001-01-26 | Treatment of cardiovascular disease with quinolinone enantiomers |
US10/435,999 Abandoned US20050009866A1 (en) | 2001-01-26 | 2003-05-12 | Treatment of cardiovascular disease with quinolinone enantiomers |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/771,104 Expired - Fee Related US6562838B2 (en) | 2001-01-26 | 2001-01-26 | Treatment of cardiovascular disease with quinolinone enantiomers |
Country Status (1)
Country | Link |
---|---|
US (2) | US6562838B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4302460A (en) * | 1979-03-27 | 1981-11-24 | The Boots Company Limited | 4-Quinolinones having antihypertensive activity |
US4311707A (en) * | 1979-02-12 | 1982-01-19 | American Cyanamid Company | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions |
US4522884A (en) * | 1981-05-13 | 1985-06-11 | Imperial Chemical Industries Plc | Process of melt spinning polypropylene and novel rough surfaced fibres produced thereby |
US4552891A (en) * | 1983-09-13 | 1985-11-12 | Eli Lilly And Company | Benzothiophene derivatives |
US4623650A (en) * | 1984-12-06 | 1986-11-18 | Pfizer Inc. | Antibiotic derivatives of 7-phenyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids |
US4710506A (en) * | 1985-06-15 | 1987-12-01 | The Boots Company Plc | Antihypertensive thienopyridines |
US4772614A (en) * | 1985-06-15 | 1988-09-20 | The Boots Company | Quinolone sulphonamides useful as antihypertensive agents |
US4855291A (en) * | 1984-08-15 | 1989-08-08 | The Boots Company Plc | 1,4dihydroquinoline-3-carboxamides |
US4877793A (en) * | 1986-11-20 | 1989-10-31 | The Boots Company, Plc | Thieno[3,2-b]pyridine-6-carboxamide compounds useful in treating hypertension |
US4997840A (en) * | 1988-02-22 | 1991-03-05 | The Boots Company, Plc | Quinolone sulphonates having antihypertensive activity |
US5011931A (en) * | 1987-11-18 | 1991-04-30 | The Boots Company Plc | Process for the preparation of 1-methyl-3-methylthio-4-quinolone and the sulfinyl, and sulfonyl analogs thereof |
US5393773A (en) * | 1991-01-24 | 1995-02-28 | Glaxo Group Limited | Method for the intranasal administration of 3-[2-(dimethylamino)-ethyl]-H-methyl-1H-indole-5-methanesulphonamide |
US5554639A (en) * | 1990-12-12 | 1996-09-10 | Glaxo Group Limited | Medicaments |
US5721238A (en) * | 1995-01-19 | 1998-02-24 | Bayer Aktiengesellschaft | 2,8-disubstituted quinazolinones |
US5801161A (en) * | 1993-12-20 | 1998-09-01 | Merkus; Franciscus W. H. M. | Pharmaceutical composition for the intranasal administration of hydroxocobalamin |
US5864037A (en) * | 1996-06-06 | 1999-01-26 | Euro-Celtique, S.A. | Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity |
US5869479A (en) * | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
US6110489A (en) * | 1998-05-01 | 2000-08-29 | Cutler; Neal R. | Use of quinolines and quinolones to treat male erectile dysfunction |
US6132757A (en) * | 1998-05-01 | 2000-10-17 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
US6132753A (en) * | 1998-05-01 | 2000-10-17 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
US6187790B1 (en) * | 1999-03-04 | 2001-02-13 | Neal R. Cutler | Use of cilostazol for treatment of sexual dysfunction |
US6194433B1 (en) * | 1998-10-05 | 2001-02-27 | Neal R. Cutler | Sexual dysfunction in females |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2345192A (en) | 1992-07-21 | 1994-02-14 | Boots Company Plc, The | Use of 7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone in the treatment of angina pectoris |
EP1107759A1 (en) | 1998-08-03 | 2001-06-20 | Basf Corporation | Pyridinones for the treatment of sexual dysfunction |
-
2001
- 2001-01-26 US US09/771,104 patent/US6562838B2/en not_active Expired - Fee Related
-
2003
- 2003-05-12 US US10/435,999 patent/US20050009866A1/en not_active Abandoned
Patent Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4311707A (en) * | 1979-02-12 | 1982-01-19 | American Cyanamid Company | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions |
US4302460A (en) * | 1979-03-27 | 1981-11-24 | The Boots Company Limited | 4-Quinolinones having antihypertensive activity |
US4522884A (en) * | 1981-05-13 | 1985-06-11 | Imperial Chemical Industries Plc | Process of melt spinning polypropylene and novel rough surfaced fibres produced thereby |
US4552891A (en) * | 1983-09-13 | 1985-11-12 | Eli Lilly And Company | Benzothiophene derivatives |
US4855291A (en) * | 1984-08-15 | 1989-08-08 | The Boots Company Plc | 1,4dihydroquinoline-3-carboxamides |
US4623650A (en) * | 1984-12-06 | 1986-11-18 | Pfizer Inc. | Antibiotic derivatives of 7-phenyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids |
US4710506A (en) * | 1985-06-15 | 1987-12-01 | The Boots Company Plc | Antihypertensive thienopyridines |
US4772614A (en) * | 1985-06-15 | 1988-09-20 | The Boots Company | Quinolone sulphonamides useful as antihypertensive agents |
US4877793A (en) * | 1986-11-20 | 1989-10-31 | The Boots Company, Plc | Thieno[3,2-b]pyridine-6-carboxamide compounds useful in treating hypertension |
US5011931A (en) * | 1987-11-18 | 1991-04-30 | The Boots Company Plc | Process for the preparation of 1-methyl-3-methylthio-4-quinolone and the sulfinyl, and sulfonyl analogs thereof |
US5079264A (en) * | 1987-11-18 | 1992-01-07 | The Boots Co. Plc | Chemical process |
US4997840A (en) * | 1988-02-22 | 1991-03-05 | The Boots Company, Plc | Quinolone sulphonates having antihypertensive activity |
US5554639A (en) * | 1990-12-12 | 1996-09-10 | Glaxo Group Limited | Medicaments |
US5393773A (en) * | 1991-01-24 | 1995-02-28 | Glaxo Group Limited | Method for the intranasal administration of 3-[2-(dimethylamino)-ethyl]-H-methyl-1H-indole-5-methanesulphonamide |
US5801161A (en) * | 1993-12-20 | 1998-09-01 | Merkus; Franciscus W. H. M. | Pharmaceutical composition for the intranasal administration of hydroxocobalamin |
US5721238A (en) * | 1995-01-19 | 1998-02-24 | Bayer Aktiengesellschaft | 2,8-disubstituted quinazolinones |
US5864037A (en) * | 1996-06-06 | 1999-01-26 | Euro-Celtique, S.A. | Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity |
US5869479A (en) * | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
US6110489A (en) * | 1998-05-01 | 2000-08-29 | Cutler; Neal R. | Use of quinolines and quinolones to treat male erectile dysfunction |
US6132757A (en) * | 1998-05-01 | 2000-10-17 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
US6132753A (en) * | 1998-05-01 | 2000-10-17 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
US6194433B1 (en) * | 1998-10-05 | 2001-02-27 | Neal R. Cutler | Sexual dysfunction in females |
US6187790B1 (en) * | 1999-03-04 | 2001-02-13 | Neal R. Cutler | Use of cilostazol for treatment of sexual dysfunction |
Also Published As
Publication number | Publication date |
---|---|
US6562838B2 (en) | 2003-05-13 |
US20020143031A1 (en) | 2002-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6451813B1 (en) | Treatment of gastroparesis in certain patient groups | |
JP6882265B2 (en) | Use of cowlan compounds in the manufacture of therapeutic agents for cardiac hypertrophy and pulmonary hypertension | |
JP4174673B2 (en) | Pharmaceutical composition for the treatment of interstitial cystitis | |
JPH06234637A (en) | Use of leflunomide for inhibiting tumor necrosis factor alpha | |
US6562838B2 (en) | Treatment of cardiovascular disease with quinolinone enantiomers | |
US7041677B2 (en) | Use of monochloroflosequinan in the treatment of sexual dysfunction | |
RU2542455C2 (en) | Otamixaban for treating non-st elevation myocardial infarction in senior patients and patients suffering disturbed renal function | |
JP2015512919A (en) | Lercanidipine hydrochloride and losartan potassium combination and preparation method thereof | |
US6995173B2 (en) | Methods for the treatment of central nervous system disorders in certain patient groups | |
CN109806263A (en) | A kind of pharmaceutical composition and its preparation method and application | |
US8431606B2 (en) | Medicament for treating schizophrenia comprising cilostazol | |
US6541487B1 (en) | PDE III inhibitors for treating sexual dysfunction | |
WO2010114562A1 (en) | Improved methods of administration of k201 (jtv-519) (4-[3-{1-(4-benzyl) piperidinyl}propionyl]-7-methoxy 2, 3, 4, 5-tetrahydro-1, 4-benzothiazepine monohydrochloride) | |
WO2002058703A2 (en) | The treatment of sexual dysfunction and cardiovascular disease with quinolinone enantiomers | |
US4439442A (en) | Naftidrofuryl citrate and therapeutic applications | |
US20230087361A1 (en) | Use of dianthrone compound in preparation of medicament for prevention and/or treatment of myocardial ischemic disease and related disease thereof | |
JP2002145770A (en) | Pharmaceutical composition for prophylaxis or treatment of cardiac insufficiency | |
AU2002243690A1 (en) | The treatment of sexual dysfunction and cardiovascular disease with quinolinone enantiomers | |
AU2021258979B2 (en) | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | |
JP5437331B2 (en) | Pharmaceutical composition and method for improving cardiac function | |
US5032601A (en) | Venous extensibility improving and cardiac hypertrophy suppressant agent containing a dihydropyridine compound | |
WO2024086819A2 (en) | Diagnosis and treatment of heart failure | |
JP3247763B2 (en) | Pharmaceutical for the treatment of nerve damage caused by interruption of blood circulation consisting of xanthine derivatives | |
WO2024073367A1 (en) | Treatment of acute cannabinoid overdose | |
JPS63218622A (en) | Remedy and prophylactic for ischemic heart diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: R.T. ALAMO VENTURES I, L.L.C., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CUTLER, NEAL R.;SRAMEK, JOHN;REEL/FRAME:014628/0457 Effective date: 20031014 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |